 [ 
   

  {
    "prompt": "What is the role of the PD-1/PD-L1 pathway in immune regulation?",
    "completion": "The PD-1/PD-L1 pathway is a key immune checkpoint that downregulates immune responses by inhibiting T-cell function upon ligand binding, helping to maintain peripheral tolerance and prevent autoimmunity."
  },
  {
    "prompt": "Where is PD-1 expressed in the immune system?",
    "completion": "PD-1 is a transmembrane protein expressed primarily on activated T cells, B cells, and macrophages."
  },
  {
    "prompt": "What happens when PD-1 binds to PD-L1 or PD-L2?",
    "completion": "Binding of PD-1 to its ligands PD-L1 or PD-L2 downregulates T-cell activity, reducing IL-2 and IFNγ production."
  },
  {
    "prompt": "How is PD-L1 expression regulated on immune and non-immune cells?",
    "completion": "PD-L1 expression is regulated by inflammatory cytokines such as IFNγ and can be induced on T cells, epithelial, and endothelial cells in addition to antigen-presenting cells."
  },
  {
    "prompt": "What other receptor can PD-L1 bind to besides PD-1?",
    "completion": "PD-L1 can also bind to B7.1 (CD80), though the functional impact of this interaction is less well understood."
  },
  {
    "prompt": "How is soluble PD-L1 formed and what is its relevance?",
    "completion": "Soluble PD-L1 is generated by alternative splicing of PD-L1 mRNA and may regulate immune responses in a paracrine manner within the tumor microenvironment."
  },
  {
    "prompt": "What are the common molecular drivers of PD-L1 expression in tumors?",
    "completion": "Factors such as inflammatory cytokines, PI3K–Akt and MAPK pathway activation, STAT1 signaling, and epigenetic regulation by miRNAs influence PD-L1 expression."
  },
  {
    "prompt": "How is PD-L1 expression linked to outcomes in bladder cancer?",
    "completion": "In bladder cancer, PD-L1 expression is associated with higher tumor grade, advanced stage, poor response to BCG immunotherapy, and worse survival outcomes."
  },
  {
    "prompt": "What is atezolizumab and how does it act on the PD-L1 pathway?",
    "completion": "Atezolizumab is a fully humanized IgG1 monoclonal antibody that selectively blocks PD-L1 from binding to PD-1 and B7.1, enhancing T-cell-mediated antitumor immunity."
  },
  {
    "prompt": "Does atezolizumab block PD-L2 interactions with PD-1?",
    "completion": "No, atezolizumab does not block the interaction between PD-L2 and PD-1."
  },
  {
    "prompt": "What is the pharmacokinetic profile of atezolizumab in preclinical models?",
    "completion": "In preclinical models, atezolizumab shows limited volume of distribution consistent with plasma volume and accumulates in organs like spleen, lungs, and tumor tissue."
  },
  {
    "prompt": "How does atezolizumab distribute in tumor-bearing animals?",
    "completion": "Atezolizumab accumulates initially at the tumor periphery and later penetrates the tumor core, particularly in necrotic areas."
  },
  {
    "prompt": "Why is the pharmacokinetics of atezolizumab nonlinear?",
    "completion": "Atezolizumab exhibits nonlinear pharmacokinetics due to target-mediated drug disposition involving binding to PD-L1 receptors."
  },
  {
    "prompt": "At what serum concentration does PD-L1 receptor saturation occur with atezolizumab?",
    "completion": "Saturation of PD-L1 on CD4 and CD8 T cells occurs at serum concentrations above 0.5 μg/mL, typically between 24–48 hours after dosing."
  },



  {
    "prompt": "What is the NCT number of the phase I trial evaluating atezolizumab dosing in solid tumors?",
    "completion": "NCT01375842 (PCD4989G) is the Phase I trial evaluating atezolizumab in metastatic solid tumors."
  },
  {
    "prompt": "What was the dosing range of atezolizumab in the PCD4989G trial?",
    "completion": "Atezolizumab was administered at doses ranging from 0.03 to 20 mg/kg every 3 weeks."
  },
  {
    "prompt": "What trough level is required for 95% saturation of intratumoral PD-L1 receptors in murine models?",
    "completion": "A trough level greater than 6 μg/mL results in over 95% saturation of PD-L1 receptors in murine models."
  },
  {
    "prompt": "What is the proposed optimal dose of atezolizumab for future studies?",
    "completion": "The proposed optimal dose is 1,200 mg, assuming an 80 kg person."
  },
  {
    "prompt": "How long is the infusion time for atezolizumab in initial and subsequent cycles?",
    "completion": "Atezolizumab is infused over 60 minutes for the first cycle and 30 minutes in subsequent cycles if well tolerated."
  },
  {
    "prompt": "What are the pharmacokinetic characteristics of atezolizumab?",
    "completion": "Volume of distribution is 6.9 L, half-life is 27 days, and steady-state is reached by week 9 (cycle 3)."
  },
  {
    "prompt": "What is the incidence of anti-therapeutic antibodies (ATAs) in patients treated with atezolizumab?",
    "completion": "42% of patients in the phase I trial developed ATAs at some point, though these did not affect PK, efficacy, or safety."
  },
  {
    "prompt": "When do anti-therapeutic antibodies appear in preclinical models?",
    "completion": "In mice and monkeys, ATAs begin to develop around day 7 and are present in all animals by day 14."
  },
  {
    "prompt": "Does mild hepatic or moderate renal impairment affect atezolizumab dosing?",
    "completion": "No, mild hepatic impairment and moderate renal dysfunction (GFR 30–89 mL/min) do not affect dosing."
  },
  {
    "prompt": "Is atezolizumab safe in patients with severe renal or moderate hepatic impairment?",
    "completion": "The pharmacokinetics in severe renal (GFR <30 mL/min) or moderate hepatic impairment (>1.5 ULN) are unknown."
  },
  {
    "prompt": "Does atezolizumab have any known genotoxic, carcinogenic, or fertility effects?",
    "completion": "These properties are unknown; genotoxicity, carcinogenicity, and fertility effects have not been established."
  },
  {
    "prompt": "What Fc modification does atezolizumab have and why is it important?",
    "completion": "Atezolizumab has an asparagine-to-alanine substitution at position 298 in CH2 to prevent FcγR binding, thereby avoiding ADCC against PD-L1+ immune cells."
  },
  {
    "prompt": "Why is FcγR-binding deficiency important for atezolizumab's mechanism of action?",
    "completion": "It prevents antibody-dependent cell-mediated cytotoxicity (ADCC) of PD-L1+ T cells and other immune cells, preserving antitumor immunity."
  },
  {
    "prompt": "What cytokine changes are observed after atezolizumab treatment?",
    "completion": "Transient increases in IL-18, IFNγ, and CXCL11, and a transient decrease in IL-6."
  },
  {
    "prompt": "What cellular changes are associated with atezolizumab treatment in clinical trials?",
    "completion": "An increase in proliferating CD8+ T cells has been observed."
  },

  {
    "prompt": "In which trial was atezolizumab first evaluated for efficacy in bladder cancer?",
    "completion": "Atezolizumab was first evaluated in an expansion cohort of the Phase I PCD4989G trial (NCT01375842)."
  },
  {
    "prompt": "How were patients selected for the bladder cancer cohort in the early phase of the PCD4989G trial?",
    "completion": "Initially, patients were selected based on PD-L1 expression, but after 21 enrollments, the trial was opened to all bladder cancer patients regardless of PD-L1 status."
  },
  {
    "prompt": "How many patients were evaluable for efficacy in the Phase I bladder cancer cohort of the PCD4989G trial?",
    "completion": "Sixty-seven patients were evaluable for efficacy in the initial Phase I bladder cancer cohort."
  },
  {
    "prompt": "What percentage of patients in the PCD4989G bladder cancer cohort had high PD-L1 expression?",
    "completion": "15% of patients had high PD-L1 expression."
  },
  {
    "prompt": "What were the most common prior treatments in the bladder cancer cohort?",
    "completion": "93% had prior platinum-based chemotherapy, and 72% had received at least two prior systemic therapy regimens."
  },
  {
    "prompt": "What was the objective response rate (ORR) in patients with high or moderate PD-L1 expression?",
    "completion": "The ORR was 43% in the high/moderate PD-L1 expression group."
  },
  {
    "prompt": "What was the ORR in patients with low or absent PD-L1 expression in the PCD4989G bladder cohort?",
    "completion": "The ORR was 11% in the low/absent PD-L1 expression group."
  },
  {
    "prompt": "What percentage of patients achieved complete response (CR) and what was their PD-L1 expression?",
    "completion": "7% of patients achieved a complete response, and all had high or moderate PD-L1 expression."
  },
  {
    "prompt": "What was the durability of responses among the initial 17 responders in the Phase I cohort?",
    "completion": "As of data lock, 16 out of 17 responders had not progressed, and the median duration of response had not been reached."
  },
  {
    "prompt": "When did the FDA grant breakthrough therapy designation to atezolizumab for bladder cancer?",
    "completion": "The FDA granted breakthrough therapy designation to atezolizumab in June 2014."
  },
  {
    "prompt": "What were the Phase I bladder cancer ORR results presented at ASCO 2015 for PD-L1 subgroups?",
    "completion": "The ORR was 50% in the high/moderate PD-L1 group and 17% in the low/absent PD-L1 group."
  },
  {
    "prompt": "What was the median PFS in the high/moderate vs. low/absent PD-L1 expression groups?",
    "completion": "Median PFS was 6 months in the high/moderate PD-L1 group and 1 month in the low/absent PD-L1 group."
  },
  {
    "prompt": "What was the 1-year progression-free survival (PFS) rate for patients with high/moderate PD-L1 expression?",
    "completion": "The 1-year PFS rate was 39% in the high/moderate PD-L1 expression group."
  },
  {
    "prompt": "What was the median OS in the low/absent PD-L1 group?",
    "completion": "Median overall survival in the low/absent PD-L1 group was 7.6 months."
  },
  {
    "prompt": "What was the 1-year overall survival (OS) rate for the high/moderate PD-L1 group?",
    "completion": "The 1-year OS rate was 57% in the high/moderate PD-L1 group."
  },

  {
    "prompt": "What is the IMvigor210 trial and what was its design?",
    "completion": "IMvigor210 (NCT02108652) is a multicenter, single-arm, two-cohort phase II trial of atezolizumab in bladder cancer."
  },
  {
    "prompt": "What were the inclusion criteria for cohort 2 of IMvigor210?",
    "completion": "Cohort 2 included patients with inoperable locally advanced or metastatic urothelial carcinoma who had progressed after prior platinum-based chemotherapy."
  },
  {
    "prompt": "How many patients were evaluable for efficacy in cohort 2 of IMvigor210?",
    "completion": "310 patients were evaluable for efficacy in cohort 2."
  },
  {
    "prompt": "What were the PD-L1 expression levels among patients in cohort 2 of IMvigor210?",
    "completion": "32% had high/moderate PD-L1 expression, 37% had low PD-L1, and 33% had absent PD-L1 expression."
  },
  {
    "prompt": "What was the overall response rate (ORR) in cohort 2 of IMvigor210?",
    "completion": "The overall response rate (ORR) was 15%, including a complete response (CR) rate of 5%."
  },
  {
    "prompt": "What was the ORR by PD-L1 subgroup in cohort 2 of IMvigor210?",
    "completion": "ORR was 26% in the high/moderate PD-L1 group, 11% in the low PD-L1 group, and 8% in the absent PD-L1 group."
  },
  {
    "prompt": "What were the median PFS and OS in cohort 2 of IMvigor210?",
    "completion": "Median progression-free survival (PFS) was 2.1 months, and median overall survival (OS) was 7.9 months."
  },
  {
    "prompt": "What FDA approval did atezolizumab receive based on IMvigor210 results?",
    "completion": "Atezolizumab was approved for patients with locally advanced or metastatic urothelial carcinoma who progressed after platinum-based chemotherapy or within 12 months of neoadjuvant/adjuvant chemotherapy."
  },
  {
    "prompt": "Who were the patients included in cohort 1 of IMvigor210?",
    "completion": "Cohort 1 included chemotherapy-naïve, cisplatin-ineligible patients with metastatic bladder cancer."
  },
  {
    "prompt": "What was the most common reason for cisplatin ineligibility in cohort 1?",
    "completion": "Renal dysfunction was the most common reason, seen in 71% of patients."
  },
  {
    "prompt": "What was the ORR and CR rate in cohort 1 of IMvigor210?",
    "completion": "The ORR was 24% and the complete response (CR) rate was 7%."
  },
  {
    "prompt": "What was the ORR among high/moderate PD-L1 expressers in cohort 1?",
    "completion": "The ORR was 28% among patients with high or moderate PD-L1 expression."
  },
  {
    "prompt": "What was the response rate for upper tract urothelial carcinoma in cohort 1?",
    "completion": "The ORR was 42% in patients with primary tumors in the renal pelvis or ureter."
  },
  {
    "prompt": "What were the median OS and 1-year OS rate in cohort 1?",
    "completion": "Median OS was 14.8 months, and the 1-year OS rate was 57%."
  },
  {
    "prompt": "How did the 1-year OS from IMvigor210 compare to historical second-line therapies?",
    "completion": "The 1-year OS in cohort 2 was 36%, nearly double the 20% average from 10 previous phase II trials."
  },
  {
    "prompt": "What is the purpose of the ongoing IMvigor211 trial?",
    "completion": "IMvigor211 is a randomized Phase III trial comparing atezolizumab with standard chemotherapy in platinum-refractory metastatic urothelial carcinoma."
  },
  {
    "prompt": "How did atezolizumab compare to historical controls in cisplatin-ineligible patients?",
    "completion": "Although the ORR (24%) was lower than that for gemcitabine/carboplatin (36%), the median OS (14.8 months vs. 9.3 months) appeared superior."
  },

  {
    "prompt": "How is atezolizumab generally tolerated in bladder cancer patients?",
    "completion": "Atezolizumab is generally well tolerated in bladder cancer patients, with most adverse events being mild to moderate in severity."
  },
  {
    "prompt": "Why is the tolerability of atezolizumab particularly important in bladder cancer?",
    "completion": "Many bladder cancer patients are elderly with multiple comorbidities, making them poor candidates for chemotherapy, so a tolerable immunotherapy like atezolizumab is advantageous."
  },
  {
    "prompt": "What percentage of patients in IMvigor210 experienced any adverse event (AE)?",
    "completion": "97% of patients experienced at least one adverse event of any grade."
  },
  {
    "prompt": "What proportion of patients had grade 3 or 4 adverse events in IMvigor210?",
    "completion": "55% of patients experienced grade 3 or 4 adverse events."
  },
  {
    "prompt": "What were the most common any-grade adverse events observed in IMvigor210?",
    "completion": "Fatigue (49%), nausea (26%), decreased appetite (27%), pyrexia (22%), and diarrhea (20%)."
  },
  {
    "prompt": "What were the most common grade ≥3 adverse events in IMvigor210?",
    "completion": "Anemia (9%), fatigue (6%), dyspnea (4%), nausea (2%), and hypertension (2%)."
  },
  {
    "prompt": "What percentage of patients had treatment-related adverse events (trAEs)?",
    "completion": "69% of patients had treatment-related adverse events."
  },
  {
    "prompt": "What percentage of patients had high-grade (grade ≥3) treatment-related AEs?",
    "completion": "16% of patients experienced high-grade treatment-related AEs."
  },
  {
    "prompt": "What were the most common treatment-related adverse events (trAEs)?",
    "completion": "Fatigue (30%), nausea (14%), decreased appetite (12%), pruritus (10%), pyrexia (9%), diarrhea (8%), rash (7%), arthralgia (7%), and vomiting (6%)."
  },
  {
    "prompt": "Were there any treatment-related deaths in the IMvigor210 trial?",
    "completion": "No treatment-related deaths were reported."
  },
  {
    "prompt": "How often was atezolizumab treatment interrupted or discontinued due to AEs?",
    "completion": "Treatment was interrupted in 20% of patients and discontinued in 4% due to adverse events."
  },
  {
    "prompt": "What percentage of patients experienced immune-related adverse events (irAEs)?",
    "completion": "7% of patients experienced immune-related adverse events."
  },
  {
    "prompt": "What were the most common immune-related AEs reported in IMvigor210?",
    "completion": "Pneumonitis, increased liver enzymes, rash, and dyspnea, each occurring in approximately 1% of patients."
  },
  {
    "prompt": "How often was systemic corticosteroid treatment required during IMvigor210?",
    "completion": "22% of patients required systemic corticosteroids for the management of adverse events."
  },
  {
    "prompt": "How are moderate immune-related AEs managed in patients receiving atezolizumab?",
    "completion": "Moderate irAEs are typically managed by temporarily withholding atezolizumab and using topical or systemic corticosteroids, followed by treatment reinitiation once resolved."
  },
  {
    "prompt": "Which severe irAEs typically preclude further treatment with atezolizumab?",
    "completion": "Severe irAEs like pneumonitis, hepatitis, colitis, endocrinopathies, neurologic and ocular toxicities, and pancreatitis usually preclude continued atezolizumab therapy."
  },


  {
    "prompt": "Why is PD-L1 considered a key biomarker for atezolizumab response?",
    "completion": "PD-L1 is the primary target of atezolizumab, and its expression on tumor-infiltrating immune cells (ICs) or tumor cells has been associated with response to PD-L1 blockade."
  },
  {
    "prompt": "What are the two main forms in which PD-L1 can be measured?",
    "completion": "PD-L1 can be measured as membrane-bound on cells or as a soluble protein in biofluids."
  },
  {
    "prompt": "Why is it difficult to define the most relevant PD-L1 measurement for response prediction?",
    "completion": "It's unclear whether PD-L1 on tumor cells, immune cells, endothelial cells, or in soluble form best predicts outcome, and multiple factors affect test variability."
  },
  {
    "prompt": "What variables influence the accuracy of PD-L1 measurement in assays?",
    "completion": "Variables include the antibody clone used, positivity cutoff points, detection method (IHC, qPCR, ELISA), and sample timing and location."
  },
  {
    "prompt": "What effort has been made to standardize PD-L1 testing?",
    "completion": "A blueprint proposal was initiated during the FDA-AACR-ASCO workshop in 2015 to harmonize PD-L1 assays and companion diagnostic development."
  },
  {
    "prompt": "Is PD-L1 expression always predictive of atezolizumab response?",
    "completion": "No. Although PD-L1–positive tumors respond more often, responses have also been seen in PD-L1–negative tumors."
  },
  {
    "prompt": "Which assay is FDA-approved for atezolizumab companion diagnostic use in bladder cancer?",
    "completion": "The Ventana SP142 IHC assay is approved as a companion diagnostic for atezolizumab."
  },
  {
    "prompt": "What does the Ventana SP142 assay measure specifically?",
    "completion": "It measures PD-L1 expression on tumor-infiltrating immune cells (ICs) and categorizes them into IC0 (<1%), IC1 (1%–5%), IC2 (5%–10%), and IC3 (≥10%)."
  },
  {
    "prompt": "What did the IMvigor210 trial find regarding tumor cell PD-L1 expression?",
    "completion": "IMvigor210 found that tumor-infiltrating immune cell PD-L1 expression, not tumor cell PD-L1, predicted atezolizumab response."
  },
  {
    "prompt": "Why is tumor cell PD-L1 expression still considered relevant despite IMvigor210 results?",
    "completion": "Tumor cell PD-L1 expression is often correlated with immune cell infiltration, which reflects a responsive tumor microenvironment."
  },
  {
    "prompt": "What changes in PD-L1 expression were observed in tumors responding to atezolizumab?",
    "completion": "PD-L1 expression increased in responding tumors during serial biopsies, reflecting immune reactivation."
  },
  {
    "prompt": "What other potential biomarkers beyond PD-L1 may predict response to atezolizumab in bladder cancer?",
    "completion": "The Cancer Genome Atlas (TCGA) molecular subtype and tumor mutation load have been associated with response."
  },
  {
    "prompt": "What additional biomarkers have been linked to atezolizumab response in other cancers?",
    "completion": "These include IFNγ gene expression, dominant effector T-cell signatures, IDO expression, JAK3 activation, and other immune checkpoint molecule expression."
  },
  {
    "prompt": "Have any of the biomarkers beyond PD-L1 been fully validated for clinical use?",
    "completion": "No, most biomarkers associated with atezolizumab response are still exploratory and have not been fully validated."
  },

  {
    "prompt": "What was the basis for FDA approval of atezolizumab in metastatic bladder cancer?",
    "completion": "The FDA approved atezolizumab based on good objective response rates and durable responses observed in the IMvigor210 Phase II trial."
  },
  {
    "prompt": "Is there currently a second-line therapy in metastatic bladder cancer that has proven survival benefit?",
    "completion": "No, as of now there is no survival-prolonging second-line therapy for metastatic bladder cancer following platinum-based chemotherapy."
  },
  {
    "prompt": "Which trial is designed to provide definitive survival data for atezolizumab in second-line metastatic bladder cancer?",
    "completion": "The IMvigor211 trial is a randomized Phase III trial designed to evaluate survival benefit of atezolizumab in second-line metastatic bladder cancer."
  },
  {
    "prompt": "How many patients were enrolled in the IMvigor211 trial?",
    "completion": "IMvigor211 completed planned accrual with 932 patients enrolled."
  },
  {
    "prompt": "What is the purpose of the IMvigor130 trial?",
    "completion": "IMvigor130 is evaluating overall survival differences between atezolizumab plus gemcitabine and carboplatin versus gemcitabine and carboplatin alone in untreated, cisplatin-ineligible patients with metastatic bladder cancer."
  },
  {
    "prompt": "Why is atezolizumab being combined with chemotherapy in trials like IMvigor130?",
    "completion": "Combination therapy is being tested to potentially enhance antitumor activity and improve survival outcomes in cisplatin-ineligible patients."
  },


  {
    "prompt": "What is the design and status of the IMvigor211 trial (NCT02302807)?",
    "completion": "IMvigor211 is a Phase III trial in second-line metastatic or locally advanced bladder cancer patients who failed platinum therapy, comparing atezolizumab to investigator's choice chemotherapy. Accrual is complete."
  },
  {
    "prompt": "What is the primary outcome of IMvigor211 (NCT02302807)?",
    "completion": "The primary outcome of IMvigor211 is overall survival (OS)."
  },
  {
    "prompt": "What is the trial design of IMvigor130 (NCT02807636)?",
    "completion": "IMvigor130 is a Phase III trial in first-line cisplatin-ineligible metastatic bladder cancer patients, comparing atezolizumab plus gemcitabine/carboplatin to placebo plus gemcitabine/carboplatin. It is currently recruiting patients."
  },
  {
    "prompt": "What are the primary outcomes of IMvigor130?",
    "completion": "Progression-free survival (PFS) and overall survival (OS)."
  },
  {
    "prompt": "What is the purpose of the IMvigor010 trial (NCT02450331)?",
    "completion": "IMvigor010 is a Phase III adjuvant trial evaluating atezolizumab for 1 year vs. observation in patients with muscle-invasive bladder cancer post-cystectomy. It is currently recruiting."
  },
  {
    "prompt": "What is the primary endpoint of the IMvigor010 trial?",
    "completion": "The primary endpoint is disease-free survival (DFS)."
  },
  {
    "prompt": "What is the ABACUS trial (NCT02662309)?",
    "completion": "ABACUS is a Phase II trial of two cycles of atezolizumab before cystectomy in cisplatin-ineligible muscle-invasive bladder cancer patients. It is currently recruiting."
  },
  {
    "prompt": "What are the endpoints of the ABACUS trial?",
    "completion": "The endpoints are response rate and immune monitoring."
  },
  {
    "prompt": "What is being tested in trial NCT02451423?",
    "completion": "This is a Phase II trial in BCG-refractory non-muscle–invasive and cisplatin-ineligible muscle-invasive bladder cancer, using sequential 3-week cycles of atezolizumab. It is currently recruiting."
  },
  {
    "prompt": "What are the outcomes for trial NCT02451423?",
    "completion": "Response rate and immune monitoring are the primary outcomes."
  },
  {
    "prompt": "What is the GU123 trial (NCT02792192)?",
    "completion": "GU123 is a Phase Ib/II trial evaluating BCG plus atezolizumab in BCG-refractory non-muscle–invasive bladder cancer. It is currently recruiting patients."
  },
  {
    "prompt": "What is the endpoint for the GU123 trial?",
    "completion": "The primary endpoint is disease-free survival (DFS)."
  },

  {
    "prompt": "What is the only systemic therapy currently proven to extend survival in muscle-invasive bladder cancer (MIBC)?",
    "completion": "Cisplatin-based systemic chemotherapy is the only proven systemic therapy that extends survival in patients with muscle-invasive bladder cancer undergoing curative cystectomy."
  },
  {
    "prompt": "Why do many muscle-invasive bladder cancer patients not receive cisplatin-based chemotherapy?",
    "completion": "Many patients are ineligible due to comorbidities such as renal impairment or poor performance status."
  },
  {
    "prompt": "What is the goal of the IMvigor010 trial in bladder cancer?",
    "completion": "IMvigor010 is designed to determine whether adjuvant atezolizumab improves survival in patients with residual muscle-invasive bladder cancer after cystectomy."
  },
  {
    "prompt": "Which trial is investigating atezolizumab in BCG-unresponsive non-muscle–invasive bladder cancer (NMIBC)?",
    "completion": "The GU123 trial is evaluating atezolizumab in combination with BCG in patients with BCG-unresponsive non-muscle–invasive bladder cancer."
  },
  {
    "prompt": "Why are IMvigor010 and GU123 trials important for the future of bladder cancer treatment?",
    "completion": "These trials will help define atezolizumab's role across localized and non-muscle–invasive bladder cancer stages, potentially expanding its use beyond metastatic disease."
  },


  {
    "prompt": "What are rate-limiting mutations in cancer development?",
    "completion": "Rate-limiting mutations are rare genetic alterations that confer a significant proliferative and survival advantage to cells, enabling clonal expansion and increasing the risk of malignant transformation."
  },
  {
    "prompt": "Why are most mutations in somatic cells not considered rate-limiting?",
    "completion": "Most somatic mutations have little or no positive effect on cell growth and do not significantly contribute to cancer progression."
  },
  {
    "prompt": "What happens once a rate-limiting mutation occurs in a tissue?",
    "completion": "It allows the expansion of a precancerous cell population, increasing the chance of additional somatic mutations that can lead to full malignancy."
  },
  {
    "prompt": "How does the two-hit hypothesis explain inherited cancer syndromes?",
    "completion": "The two-hit hypothesis states that individuals with an inherited mutation in one allele of a tumor suppressor gene require only a second somatic mutation in the remaining allele to initiate cancer, making cancer more likely and earlier in onset."
  },
  {
    "prompt": "What gene is involved in retinoblastoma and how does it demonstrate the two-hit hypothesis?",
    "completion": "The RB1 gene is involved; inherited inactivation of one RB1 allele followed by somatic inactivation of the second allele initiates retinoblastoma, especially in familial cases where it often presents bilaterally and at an earlier age."
  },
  {
    "prompt": "Why is sporadic retinoblastoma less common than inherited forms?",
    "completion": "In sporadic cases, both RB1 alleles must be randomly inactivated in the same somatic cell, a statistically rare event, leading to later onset and typically unifocal tumors."
  },
  {
    "prompt": "Which cancers are also explained by the two-hit model beyond retinoblastoma?",
    "completion": "The model also explains hereditary non-polyposis colorectal cancer, hereditary breast and ovarian cancer, neurofibromatosis types 1 and 2, and familial adenomatous polyposis coli."
  },
  {
    "prompt": "Who proposed the two-hit hypothesis and for what purpose?",
    "completion": "Alfred Knudson proposed the two-hit hypothesis to explain the age of onset and bilateral presentation in familial pediatric cancers like retinoblastoma."
  },


  {
    "prompt": "What is genetic heterogeneity in the context of cancer predisposition?",
    "completion": "Genetic heterogeneity refers to the fact that mutations in different genes can cause similar cancer syndromes, as seen in HNPCC where mutations in multiple mismatch-repair genes can lead to colon cancer."
  },
  {
    "prompt": "Which genes are commonly mutated in hereditary non-polyposis colon cancer (HNPCC)?",
    "completion": "HNPCC commonly involves mutations in MSH2, MLH1, PMS1, PMS2, and MSH6 genes."
  },
  {
    "prompt": "What is the clinical significance of APC gene mutations in familial polyposis?",
    "completion": "APC gene mutations lead to the development of hundreds to thousands of colon polyps by age 30 and a high risk of colorectal cancer by age 40, making prophylactic colectomy a key management strategy."
  },
  {
    "prompt": "How does allelic variation in APC affect colorectal cancer risk in Ashkenazi Jews?",
    "completion": "About 6% of Ashkenazi Jews carry a common APC variant (I1307K) that increases colorectal cancer risk two-fold despite having normal protein function and no polyposis phenotype."
  },
  {
    "prompt": "How does the mismatch-repair defect in HNPCC contribute to cancer?",
    "completion": "Inactivation of mismatch-repair genes results in error-prone DNA repair and accumulation of mutations in genes that regulate cell proliferation, such as the TGF-β receptor."
  },
  {
    "prompt": "Why is there variability in clinical presentation among individuals with the same mismatch-repair gene mutation in HNPCC?",
    "completion": "Phenotypic variability suggests that other genetic, environmental, or lifestyle factors influence cancer risk beyond the primary mutation."
  },
  {
    "prompt": "Which cancers are associated with HNPCC besides colorectal cancer?",
    "completion": "HNPCC is also linked to endometrial, ovarian, gastric, hepatobiliary, urinary tract, brain tumors, and lymphomas."
  },
  {
    "prompt": "What genes are associated with inherited breast cancer risk?",
    "completion": "BRCA1 and BRCA2 gene mutations are associated with increased risk of breast and ovarian cancer."
  },
  {
    "prompt": "What is the estimated lifetime breast cancer risk for BRCA mutation carriers?",
    "completion": "The lifetime risk is estimated to be between 60% and 80% for BRCA1 or BRCA2 mutation carriers."
  },
  {
    "prompt": "How do BRCA2 mutations affect male carriers?",
    "completion": "BRCA2 mutations increase the risk of breast cancer in men and also raise the risk of pancreatic cancer in both sexes."
  },
  {
    "prompt": "What is a founder effect, and how does it relate to BRCA mutations in Ashkenazi Jews?",
    "completion": "A founder effect refers to the inheritance of specific BRCA mutations from a common ancestor, which explains the high frequency of three mutations in the Ashkenazi Jewish population."
  },
  {
    "prompt": "Why is genetic testing for BRCA mutations considered more controversial?",
    "completion": "Because of challenges in early detection of breast/ovarian cancer and the psychological and physical implications of preventive surgeries like mastectomy or oophorectomy."
  },
  {
    "prompt": "What percentage of women under age 40 with breast cancer have BRCA mutations?",
    "completion": "Around 10% have BRCA1 mutations and 2–3% have BRCA2 mutations, regardless of family history."
  },


  {
    "prompt": "What is a major issue in managing patients with inherited cancer syndromes?",
    "completion": "A major issue is the lack of specialized genetic counsellors and oncologists, despite growing awareness and demand for genetic testing and personalized management strategies."
  },
  {
    "prompt": "Why is awareness of family history critical in inherited cancer syndromes?",
    "completion": "Recognizing a family history can guide surveillance strategies and inform decisions about genetic testing, even before test results are available."
  },
  {
    "prompt": "What are the key concerns around genetic testing in cancer patients in the USA?",
    "completion": "There is concern about genetic discrimination affecting insurance and employment, which has led to hesitation in pursuing genetic testing."
  },
  {
    "prompt": "What factors influence clinical recommendations after identifying a cancer predisposition mutation?",
    "completion": "Clinical recommendations depend on the estimated cancer risk from the mutation and the availability and effectiveness of early detection or preventive strategies."
  },
  {
    "prompt": "Why is BRCA testing more controversial than RB1 testing?",
    "completion": "Because the at-risk population is less well defined, early detection is more difficult, and the preventive measures such as prophylactic surgeries are more drastic."
  },
  {
    "prompt": "List criteria that might justify BRCA1/BRCA2 genetic testing.",
    "completion": "Criteria may include having multiple relatives with breast or ovarian cancer, early-onset breast cancer in a close relative, male breast cancer, or being of Ashkenazi Jewish descent."
  },
  {
    "prompt": "What is the role of prophylactic surgery in BRCA mutation carriers?",
    "completion": "Prophylactic bilateral mastectomy or oophorectomy may reduce cancer risk but does not eliminate it entirely."
  },
  {
    "prompt": "How does the study of somatic mutations contribute to cancer understanding?",
    "completion": "It reveals mutation patterns linked to carcinogen exposure, shows how viruses inactivate tumor suppressors, and helps define molecular subtypes of cancer."
  },
  {
    "prompt": "What is the significance of TP53 mutations in cancer?",
    "completion": "TP53 is the most commonly inactivated tumor-suppressor gene in human cancer, often reflecting environmental mutagen exposure."
  },
  {
    "prompt": "What viral mechanism contributes to cervical cancer development?",
    "completion": "Oncogenic HPV encodes proteins that inactivate the RB1 and TP53 tumor-suppressor proteins in host cells."
  },
  {
    "prompt": "Name a cancer defined by a specific chromosomal translocation.",
    "completion": "Chronic myeloid leukemia is defined by the BCR-ABL fusion gene from a chromosomal translocation."
  },
  {
    "prompt": "How does the BCR-ABL translocation affect cancer progression?",
    "completion": "It results in a constitutively active tyrosine kinase that drives uncontrolled proliferation in chronic myeloid leukemia."
  },
  {
    "prompt": "What genetic alteration defines acute promyelocytic leukemia?",
    "completion": "A PML-RARα translocation leading to a defective retinoic acid receptor, which makes the leukemia responsive to retinoic acid therapy."
  },
  {
    "prompt": "What is the genetic hallmark of Ewing's sarcoma?",
    "completion": "A chromosomal fusion of the EWS and Fli1 genes."
  },
  {
    "prompt": "What is the role of APC mutation in colorectal cancer?",
    "completion": "It is the initial rate-limiting mutation that initiates tumorigenesis, with additional mutations driving progression to malignancy."
  },


  {
    "prompt": "How do mutations in cancer genes affect regulatory pathways?",
    "completion": "Cancer genes often function in pathways, and a mutation in any one component can disrupt the entire growth-regulatory pathway. This means that only one mutation is needed to impair the function of the whole system."
  },
  {
    "prompt": "Why are mutations in interacting cancer genes often mutually exclusive?",
    "completion": "Because mutations in one gene within a pathway are sufficient to disrupt the function, additional mutations in interacting genes provide no selective advantage and are therefore not observed together in the same tumor."
  },
  {
    "prompt": "What is the role of RB1 in the cell cycle?",
    "completion": "RB1 encodes a protein that regulates progression through the cell cycle by controlling entry into the S-phase. It acts as a tumor suppressor and is inactivated in various cancers."
  },
  {
    "prompt": "How can the RB1 pathway be disrupted other than by RB1 mutation?",
    "completion": "Overexpression of cyclin D1, which phosphorylates and inactivates RB1, or inactivation of p16, which normally inhibits cyclin D1, can also disrupt the RB1 pathway."
  },
  {
    "prompt": "What is the significance of cyclin D1 amplification in breast cancer?",
    "completion": "Cyclin D1 amplification leads to RB1 hyperphosphorylation and inactivation, bypassing the need for direct RB1 mutations to disrupt cell cycle control."
  },
  {
    "prompt": "How is the p16 gene involved in regulating the RB1 pathway?",
    "completion": "p16 inhibits cyclin D1, thereby preventing RB1 phosphorylation and helping to maintain cell cycle control. Inactivation of p16 leads to unchecked RB1 inactivation."
  },
  {
    "prompt": "How can the TP53 pathway be disrupted without TP53 mutation?",
    "completion": "Amplification of MDM2, a p53 inhibitor, can functionally inactivate the TP53 pathway even in the absence of TP53 gene mutations."
  },
  {
    "prompt": "What gene may substitute for APC mutation in colorectal cancer?",
    "completion": "Mutations in β-catenin, an APC cofactor, can disrupt the same Wnt signaling pathway, acting as functional equivalents to APC mutations."
  },
  {
    "prompt": "Which genes are involved in basal-cell carcinoma development?",
    "completion": "Basal-cell carcinoma may have mutations in the PTCH gene or its interacting protein SMO (Smoothened), both involved in the Hedgehog signaling pathway."
  },
  {
    "prompt": "What is the role of GLI in tumors like medulloblastoma and sarcoma?",
    "completion": "GLI is a proto-oncogene regulated by PTCH; its amplification contributes to tumorigenesis in the absence of upstream Hedgehog pathway mutations."
  },
  {
    "prompt": "What does the mutual exclusivity of mutations in a pathway imply about cancer development?",
    "completion": "It suggests that disruption of a single component within a regulatory pathway is often sufficient for tumorigenesis, and additional mutations in the same pathway do not offer extra advantage."
  },


  {
    "prompt": "What are the clinical applications of somatic mutation analysis in cancer?",
    "completion": "Somatic mutation analysis can aid in early cancer detection, provide more specific diagnostic and prognostic criteria, and help predict therapeutic response or guide treatment decisions."
  },
  {
    "prompt": "Which genes commonly have gain-of-function mutations in cancer?",
    "completion": "Proto-oncogenes such as K-RAS, H-RAS, and N-RAS are frequently activated by point mutations in various cancers, leading to neoplastic transformation."
  },
  {
    "prompt": "What are common K-RAS mutation hotspots and their relevance?",
    "completion": "Codons 12, 13, and 61 of K-RAS are mutation hotspots. Mutations at these sites are present in ~50% of colorectal cancers, 80–90% of pancreatic cancers, and 30% of non-small-cell lung cancers."
  },
  {
    "prompt": "How are K-RAS mutations used in early detection of colorectal cancer?",
    "completion": "K-RAS mutations can be detected in stool samples, as these mutations are found in both colorectal carcinomas and large adenomas, indicating potential for early non-invasive diagnosis."
  },
  {
    "prompt": "What are the challenges in using K-RAS mutations for stool-based cancer screening?",
    "completion": "Challenges include difficulty in isolating DNA from colonic cells in stool and the fact that K-RAS mutations can occur in benign adenomas with low malignant potential."
  },
  {
    "prompt": "What molecular techniques have been proposed for early bladder cancer detection?",
    "completion": "Screening for deletion of the short arm of chromosome 9 (where the p16 gene resides) in urine cytology has shown high sensitivity for detecting bladder cancer."
  },
  {
    "prompt": "Why are protein and RNA markers less ideal than DNA for cancer detection?",
    "completion": "Protein markers unique to cancer are rare, and RNA is unstable and prone to degradation, making DNA—especially somatic mutations—a more reliable biomarker for early detection."
  },
  {
    "prompt": "What role do point mutations in H-RAS and N-RAS play in cancer?",
    "completion": "Point mutations in H-RAS are found in ~10–20% of bladder cancers, and N-RAS mutations occur in ~20–30% of myeloid leukemias, contributing to malignant transformation."
  },
  {
    "prompt": "What is the long-term promise of somatic mutation analysis in oncology?",
    "completion": "It may lead to earlier detection of cancers, more precise diagnostic tools, better prognostic indicators, and personalized therapeutic strategies."
  },
  {
    "prompt": "Can somatic mutation analysis replace histopathology?",
    "completion": "Not yet. While somatic mutation data adds molecular precision, it complements rather than replaces traditional histopathological and clinical staging."
  },


  {
    "prompt": "What is minimal residual disease (MRD) and how is it detected?",
    "completion": "MRD refers to the small number of cancer cells that remain in the body after treatment. It is detected using sensitive PCR-based assays that identify specific somatic mutations or chromosomal translocations."
  },
  {
    "prompt": "How are TP53 mutations used to detect cancer cell spread beyond resection borders?",
    "completion": "In head and neck cancer, TP53 mutations specific to the tumor are detected in surrounding tissues and lymph nodes, revealing spread even when histology shows no evidence of disease."
  },
  {
    "prompt": "What is the clinical relevance of detecting minimal residual disease?",
    "completion": "Detection of MRD can help predict early relapse or guide further treatment strategies, although its full clinical implications are still being evaluated in prospective studies."
  },
  {
    "prompt": "Why might somatic mutations be useful in diagnosing cancer from limited biopsy material?",
    "completion": "Somatic mutations offer molecular signatures that can distinguish between benign and malignant lesions, especially when histological data from small biopsies is inconclusive."
  },
  {
    "prompt": "Which mutations are frequently found in pancreatic cancer?",
    "completion": "K-RAS mutations are present in up to 90% of pancreatic adenocarcinomas. When combined with mutations in p16, TP53, or DPC4, they improve diagnostic accuracy."
  },
  {
    "prompt": "How can telomerase activity be used in cancer diagnosis?",
    "completion": "Telomerase activity is often elevated in malignant tumors. For example, 11 of 11 follicular thyroid carcinomas showed telomerase activity, compared to no normal thyroid tissue."
  },
  {
    "prompt": "What somatic alterations are used for prognosis in childhood leukemia?",
    "completion": "TEL-AML1 fusion indicates a good prognosis, while BCR-ABL fusion signals high risk, requiring stem-cell transplantation for optimal outcomes."
  },
  {
    "prompt": "Which gene alteration indicates poor prognosis in neuroblastoma?",
    "completion": "N-MYC gene amplification and chromosome 1p deletions are both associated with poor outcomes, regardless of clinical stage."
  },
  {
    "prompt": "How does HER2 amplification affect breast cancer prognosis?",
    "completion": "HER2 (also called ERBB2/NEU) amplification occurs in 15–20% of breast cancers and is linked to poor prognosis and aggressive tumor behavior."
  },
  {
    "prompt": "Which chromosomal change is associated with poor prognosis in colorectal cancer?",
    "completion": "Loss of chromosome 18q and altered expression of the DCC gene are linked to poor prognosis in stage II and III colorectal cancer."
  },
  {
    "prompt": "What is the principle behind E1B-deleted adenovirus therapy in cancer?",
    "completion": "E1B-deleted adenoviruses can selectively replicate in TP53-deficient cancer cells, leading to tumor-specific lysis while sparing normal cells with functional p53."
  },
  {
    "prompt": "What is a challenge in implementing TP53 gene therapy in cancer patients?",
    "completion": "One major obstacle is achieving widespread delivery of the gene to all cancer cells in the body, especially those that have metastasized."
  },
  {
    "prompt": "How might adenoviral therapies be limited in cancer treatment?",
    "completion": "Immune responses to the viral vector can reduce efficacy and limit the ability to deliver repeated doses."
  },
  {
    "prompt": "What is the broader strategy in cancer gene therapy beyond fixing single genes?",
    "completion": "It focuses on targeting entire disrupted pathways using small molecules or viral vectors to interfere with key signaling components altered in cancer."
  },

  {
    "topic": "Kinome and Phosphatome Mutational Profiling",
    "context": "The systematic mutational profiling of tyrosine kinases in non-small cell lung cancers (NSCLC) led to the discovery that clinical response to the EGFR inhibitor gefitinib is associated with activating mutations in the EGFR gene.",
    "prompt": "What are the implications of systematic mutational profiling in cancer for drug discovery?",
    "completion": "Systematic mutational analysis reveals that kinases are often altered via heterozygous missense mutations that increase catalytic activity, suggesting their role as dominant oncogenes. In contrast, tyrosine phosphatases often acquire nonsense mutations affecting both alleles, supporting their function as tumor suppressors. These findings underscore that somatic mutations—unlike differentially expressed genes—are directly selected during tumorigenesis and represent actionable therapeutic targets. Expanding such analysis to include other gene families like serine/threonine kinases, G protein signaling genes, and transcription factors may uncover new targets for cancer therapy."
  },
  {
    "topic": "Kinase gene mutations in cancer",
    "context": "Kinases in cancer are frequently altered by heterozygous missense mutations affecting catalytic domains.",
    "prompt": "Why are kinase mutations typically missense and heterozygous in cancers?",
    "completion": "Kinase mutations in cancers often involve heterozygous missense mutations because they can activate enzymatic function by altering residues critical for catalytic control. These activating mutations increase kinase activity and contribute to oncogenic signaling, typically functioning as dominant oncogenes."
  },
  {
    "topic": "Phosphatase mutations in cancer",
    "context": "Tyrosine phosphatases are frequently inactivated in cancers through nonsense or truncating mutations.",
    "prompt": "What is the functional implication of nonsense mutations in tyrosine phosphatase genes in cancer?",
    "completion": "Nonsense mutations in tyrosine phosphatase genes often lead to loss-of-function, indicating their role as tumor suppressors. These mutations frequently affect both alleles, contributing to loss of phosphatase activity and resulting in unregulated phosphorylation-driven signaling that promotes tumorigenesis."
  },
  {
    "topic": "Mutational analysis vs. gene expression profiling",
    "context": "Mutational profiling identifies fewer but more causally relevant genes compared to gene expression profiling.",
    "prompt": "How does mutational profiling differ from gene expression profiling in cancer research?",
    "completion": "Mutational profiling identifies somatic changes selected during tumorigenesis and directly involved in cancer development. In contrast, gene expression profiling often detects many differentially expressed genes, but many may not play a causal role in cancer, making mutation data more reliable for identifying therapeutic targets."
  },
  {
    "topic": "EGFR mutations and gefitinib response",
    "context": "NSCLC patients with activating EGFR mutations respond to the EGFR inhibitor gefitinib.",
    "prompt": "What is the clinical relevance of EGFR mutations in NSCLC?",
    "completion": "Activating mutations in the EGFR gene are associated with sensitivity to the tyrosine kinase inhibitor gefitinib in NSCLC. These mutations predict better clinical outcomes and guide personalized therapy for patients with EGFR-mutant tumors."
  },
  {
    "topic": "Future directions in cancer mutation analysis",
    "context": "Technological advances now allow comprehensive screening of gene families beyond kinases and phosphatases.",
    "prompt": "What other gene families should be explored for cancer-targeted therapies beyond kinases and phosphatases?",
    "completion": "Future mutational analyses should include serine/threonine kinases, transcription factors, and G-protein signaling genes. These families may harbor driver mutations and represent novel therapeutic targets, especially in tumor types not yet fully studied for somatic mutations."
  },
  {
    "topic": "Somatic mutations in cancer therapy",
    "context": "Somatic mutations selected during tumorigenesis are causally related to cancer and represent drug targets.",
    "prompt": "Why are somatic mutations considered ideal targets for anti-cancer drugs?",
    "completion": "Somatic mutations are considered ideal targets because they are causally linked to tumorigenesis. These mutations are selected during cancer development and drive tumor progression, making them highly specific and actionable targets for precision therapies."
  },
  {
    "topic": "Genetic profiling in cancer treatment",
    "context": "Genetic profiling of tumors is now central to selecting patients for targeted therapies.",
    "prompt": "How has genetic profiling changed cancer treatment in recent years?",
    "completion": "Genetic profiling has become central in oncology by allowing physicians to match patients with targeted therapies based on tumor-specific mutations. This has improved drug efficacy, reduced side effects, and led to the development of more personalized treatment approaches."
  },
  {
    "topic": "Tyrosine kinase inhibitors in precision oncology",
    "context": "Therapies targeting tyrosine kinases are effective in tumors with specific somatic mutations.",
    "prompt": "Why are tyrosine kinase inhibitors particularly effective in genetically defined cancers?",
    "completion": "Tyrosine kinase inhibitors are effective in cancers harboring activating mutations in kinase genes because these mutations drive tumor growth. By inhibiting the mutated kinase, these drugs can directly suppress tumor-promoting signaling, leading to improved outcomes."
  },
  {
    "topic": "Imatinib in personalized cancer therapy",
    "context": "Imatinib targets Bcr-Abl, KIT, and PDGFR and is effective in CML and GISTs with specific mutations.",
    "prompt": "How has imatinib revolutionized treatment in cancers like CML and GIST?",
    "completion": "Imatinib has transformed treatment by targeting the Bcr-Abl fusion protein in CML and mutated KIT or PDGFR in GISTs. Its effectiveness is closely linked to the presence of these mutations, demonstrating the power of personalized therapy based on tumor genetics."
  },
  {
    "topic": "Mutation-driven drug response in GIST",
    "context": "The dramatic response of GIST patients to imatinib correlates with KIT and PDGFR mutations.",
    "prompt": "What is the relationship between KIT/PDGFR mutations and response to imatinib in GISTs?",
    "completion": "The therapeutic response to imatinib in GISTs is strongly associated with mutations in the KIT or PDGFR genes. These mutations activate the tyrosine kinase pathway, which imatinib inhibits, leading to dramatic tumor regression in mutation-positive patients."
  },
  {
    "topic": "Targeted therapy in breast cancer",
    "context": "Trastuzumab (Herceptin) targets the HER-2 receptor and is effective mainly in breast cancer patients with HER-2 gene amplification.",
    "prompt": "Why is trastuzumab primarily effective in certain breast cancer patients?",
    "completion": "Trastuzumab is primarily effective in breast cancer patients whose tumors have HER-2 gene amplification because it targets the extracellular domain of the overexpressed HER-2 receptor, inhibiting tumor growth driven by this amplification."
  },
  {
    "topic": "EGFR-targeted therapy in lung cancer",
    "context": "Activating mutations in the EGFR gene predict response to the small molecule inhibitor gefitinib in non-small cell lung cancer.",
    "prompt": "How do EGFR mutations influence treatment outcomes with gefitinib in NSCLC patients?",
    "completion": "Activating mutations in the EGFR gene in NSCLC patients increase sensitivity to gefitinib, a tyrosine kinase inhibitor, resulting in better clinical responses compared to patients without these mutations."
  },
  {
    "topic": "Mutational profiling in cancer treatment",
    "context": "Systematic mutational profiling is key to revolutionizing clinical oncology by enabling targeted therapies.",
    "prompt": "Why is systematic mutational profiling essential for advancing cancer treatment?",
    "completion": "Systematic mutational profiling identifies specific genetic alterations in tumors, enabling personalized treatments that target those mutations. This approach improves therapeutic efficacy and opens new diagnostic and therapeutic avenues in oncology."
  },




  {
    "prompt": "Which cancer types show PTEN mutations and what are the mutation types?",
    "completion": "PTEN mutations are found in glioma, prostate, and endometrial cancers. Mutation types: Deletion (D), Missense (M), and Nonsense (N)."
  },
  {
    "prompt": "In which cancers is the PTPN3 gene mutated and what are the mutation types?",
    "completion": "PTPN3 is mutated in colon cancer. Mutation types: Missense (M) and Nonsense (N)."
  },
  {
    "prompt": "What mutations are observed in the PTPN13 gene in colon cancer?",
    "completion": "PTPN13 in colon cancer shows Missense (M), Nonsense (N), and Deletion (D) mutations."
  },
  {
    "prompt": "Which gene has only missense mutations in colon cancer?",
    "completion": "PTPN14 is mutated with only Missense (M) mutations in colon cancer."
  },
  {
    "prompt": "Name phosphatase genes mutated in both colon and lung cancers.",
    "completion": "PTPRF and PTPRT are mutated in colon and lung cancers. Mutation types include Missense (M), Nonsense (N), and Deletion (D)."
  },
  {
    "prompt": "Which phosphatase gene is mutated in colon, gastric, and lung cancers?",
    "completion": "PTPRT shows mutations in colon, gastric, and lung cancers. Mutation types: Missense (M), Nonsense (N), and Deletion (D)."
  },
  {
    "prompt": "What is the associated cancer and mutation type for Shp2/PTPN11?",
    "completion": "Shp2/PTPN11 is mutated in JMML (juvenile myelomonocytic leukemia), AML (acute myeloid leukemia), and MDS (myelodysplastic syndrome). Mutation type: Missense (M)."
  },
  


  {
    "gene": "PTEN",
    "tumors": ["Glioma", "Prostate", "Endometrial"],
    "mutations": ["Deletion", "Missense", "Nonsense"]
  },
  {
    "gene": "PTPN3",
    "tumors": ["Colon"],
    "mutations": ["Missense", "Nonsense"]
  },
  {
    "gene": "PTPN13",
    "tumors": ["Colon"],
    "mutations": ["Missense", "Nonsense", "Deletion"]
  },
  {
    "gene": "PTPN14",
    "tumors": ["Colon"],
    "mutations": ["Missense"]
  },
  {
    "gene": "PTPRF",
    "tumors": ["Colon", "Breast", "Lung"],
    "mutations": ["Missense"]
  },
  {
    "gene": "PTPRG",
    "tumors": ["Colon"],
    "mutations": ["Missense"]
  },
  {
    "gene": "PTPRT",
    "tumors": ["Colon", "Gastric", "Lung"],
    "mutations": ["Missense", "Nonsense", "Deletion"]
  },
  {
    "gene": "PTPN11",
    "alias": "Shp2",
    "tumors": ["JMML", "AML", "MDS"],
    "mutations": ["Missense"]
  },


  {
    "prompt": "What is the biological significance of kinases and phosphatases in cancer?",
    "completion": "They regulate cellular signaling by adding (kinases) or removing (phosphatases) phosphate groups, which affects proliferation and cell death."
  },
  {
    "prompt": "Which tools can be used to identify kinase and phosphatase domains in cancer-related genes?",
    "completion": "Bioinformatics tools like Hidden Markov Models (HMMs) can identify kinase and phosphatase domain-containing genes."
  },
  {
    "prompt": "Which gene families are central to signaling pathways involved in tumorigenesis?",
    "completion": "Kinases and phosphatases are central gene families in tumorigenic signaling pathways."
  },
  {
    "prompt": "How common are kinase or phosphatase mutations in colorectal cancers?",
    "completion": "More than 50% of colorectal cancers have mutations in either kinase or phosphatase genes."
  },
  {
    "prompt": "Which oncogene is commonly mutated in colorectal, breast, brain, gastric, and lung cancers?",
    "completion": "PI3KCA is one of the most commonly mutated oncogenes in various human cancers."
  },
  {
    "prompt": "What recent advancements enabled genome-wide mutational analysis of kinases and phosphatases?",
    "completion": "Genome-wide sequencing combined with computational domain identification tools enabled large-scale analysis of kinases and phosphatases in cancer."
  },
  {
    "prompt": "Which cancer types have undergone mutational analysis of tyrosine kinase receptors?",
    "completion": "Non-small cell lung cancers (NSCLC) have undergone mutational analysis of tyrosine kinase receptors."
  },
  {
    "prompt": "What does the term 'tyrosine kinome' refer to?",
    "completion": "The complete set of tyrosine kinase genes analyzed for mutations in cancer."
  },
  {
    "prompt": "Why are PI3K mutations clinically significant in cancer research?",
    "completion": "Because PI3K mutations are frequent across many tumour types, making it a potential therapeutic target."
  },

  
  {
    "prompt": "Which cancer types are associated with mutations in the ABL gene?",
    "completion": "Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL); Mutation Type: Translocation (T)"
  },
  {
    "prompt": "What type of mutation is observed in AKT2 gene in cancers?",
    "completion": "Amplification (A); Observed in ovarian and pancreatic cancers"
  },
  {
    "prompt": "In which cancers is BRAF mutated and what type of mutation occurs?",
    "completion": "BRAF has missense mutations (M) in melanoma and colon cancer"
  },
  {
    "prompt": "Which gene is commonly altered in non-small-cell lung cancer (NSCL) and glioma?",
    "completion": "EGFR with missense (M) and deletion (D) mutations"
  },
  {
    "prompt": "List cancers where ERBB2 mutations are found and the types of mutations.",
    "completion": "Breast, ovarian, and NSCL cancers; Mutations include missense (M) and amplification (A)"
  },
  {
    "prompt": "Which kinase gene has missense mutations in colorectal cancer?",
    "completion": "FES, MLK4, EPHA3, and GUCY2F all show missense mutations (M) in colorectal cancer"
  },
  {
    "prompt": "What kind of genetic alteration is found in FGFR3 in bladder and multiple myeloma?",
    "completion": "Missense (M) and translocation (T) mutations"
  },
  {
    "prompt": "What is the mutation type in JAK2 associated with AML and ALL?",
    "completion": "Translocation (T)"
  },
  {
    "prompt": "Which gene is mutated across colorectal, brain, and breast cancers and what mutation type?",
    "completion": "PIK3CA; Missense (M) and Amplification (A)"
  },
  {
    "prompt": "Which cancers show RET gene mutations and what types are they?",
    "completion": "Thyroid cancer and multiple endocrine neoplasia (MEN); Mutation types: Missense (M), Translocation (T)"
  },
  {
    "prompt": "Name a kinase gene with nonsense mutation in colon cancer.",
    "completion": "MLK4 and NTRK3 show nonsense mutations (N) in colon cancer"
  },
  {
    "prompt": "Which gene shows mutations in thyroid carcinoma and what type?",
    "completion": "NTRK1 with translocation (T)"
  },
  {
    "prompt": "What is the most frequently mutated kinase gene across multiple cancers?",
    "completion": "PIK3CA; Found mutated in colon, brain, breast, and colorectal cancers"
  },
  {
    "prompt": "What gene mutations are linked to gastrointestinal stromal tumour (GIST)?",
    "completion": "KIT and PDGFRA with missense mutations (M)"
  },

  {
    "prompt": "Which cancer types show PTEN mutations and what are the mutation types?",
    "completion": "PTEN mutations are found in glioma, prostate, and endometrial cancers. Mutation types: Deletion (D), Missense (M), and Nonsense (N)."
  },
  {
    "prompt": "In which cancers is the PTPN3 gene mutated and what are the mutation types?",
    "completion": "PTPN3 is mutated in colon cancer. Mutation types: Missense (M) and Nonsense (N)."
  },
  {
    "prompt": "What mutations are observed in the PTPN13 gene in colon cancer?",
    "completion": "PTPN13 in colon cancer shows Missense (M), Nonsense (N), and Deletion (D) mutations."
  },
  {
    "prompt": "Which gene has only missense mutations in colon cancer?",
    "completion": "PTPN14 is mutated with only Missense (M) mutations in colon cancer."
  },
  {
    "prompt": "Name phosphatase genes mutated in both colon and lung cancers.",
    "completion": "PTPRF and PTPRT are mutated in colon and lung cancers. Mutation types include Missense (M), Nonsense (N), and Deletion (D)."
  },
  {
    "prompt": "Which phosphatase gene is mutated in colon, gastric, and lung cancers?",
    "completion": "PTPRT shows mutations in colon, gastric, and lung cancers. Mutation types: Missense (M), Nonsense (N), and Deletion (D)."
  },
  {
    "prompt": "What is the associated cancer and mutation type for Shp2/PTPN11?",
    "completion": "Shp2/PTPN11 is mutated in JMML (juvenile myelomonocytic leukemia), AML (acute myeloid leukemia), and MDS (myelodysplastic syndrome). Mutation type: Missense (M)."
  },


  {
    "prompt": "What is the most common non-skin cancer among women?",
    "completion": "Breast cancer is the most common non-skin cancer among women."
  },
  {
    "prompt": "How many breast cancer survivors are there in the United States?",
    "completion": "There are more than 3.5 million breast cancer survivors in the United States."
  },
  {
    "prompt": "What percentage of female cancer survivors in the US are breast cancer survivors?",
    "completion": "Over 40% of female cancer survivors in the US are breast cancer survivors."
  },
  {
    "prompt": "What is the 5-year survival rate for early-stage breast cancer?",
    "completion": "The 5-year survival rate for early-stage breast cancer is 89%."
  },
  {
    "prompt": "What factors influence long-term side effects after breast cancer treatment?",
    "completion": "Age at diagnosis, comorbidities, treatment type, dose, and duration influence long-term side effects."
  },
  {
    "prompt": "Which treatments are associated with fatigue in breast cancer survivors?",
    "completion": "Fatigue is associated with chemotherapy and radiation therapy."
  },
  {
    "prompt": "Which breast cancer treatments are linked to cardiomyopathy?",
    "completion": "Cardiomyopathy is linked to chemotherapy, immune modulators, and radiation therapy."
  },
  {
    "prompt": "What side effects are common with hormonal therapy in breast cancer treatment?",
    "completion": "Hormonal therapy is associated with bone loss, infertility, premature menopause, vasomotor symptoms, arthralgia/myalgias, and psychosocial issues."
  },
  {
    "prompt": "Which treatment is most associated with neuropathy in breast cancer patients?",
    "completion": "Neuropathy is most associated with chemotherapy."
  },
  {
    "prompt": "What are common psychosocial side effects after breast cancer treatment?",
    "completion": "Common psychosocial side effects include anxiety, body image concerns, and depression."
  },
  {
    "prompt": "Which treatments are associated with lymphedema in breast cancer patients?",
    "completion": "Lymphedema is associated with radiation therapy and surgery."
  },
  {
    "prompt": "Which treatment is linked to pneumonitis in breast cancer patients?",
    "completion": "Pneumonitis is linked to radiation therapy."
  },
  {
    "prompt": "What are common sexual health issues after breast cancer treatment?",
    "completion": "Common sexual health issues include decreased libido, vaginal dryness, and dyspareunia, especially after chemotherapy."
  },
  {
    "prompt": "Which treatment is related to rotator cuff disease after breast cancer?",
    "completion": "Rotator cuff disease is related to surgery."
  },
  {
    "prompt": "Which treatments contribute to cognitive dysfunction in breast cancer survivors?",
    "completion": "Cognitive dysfunction is associated with chemotherapy, hormonal therapy, and surgery."
  },


  {
    "prompt": "What is lymphedema and how common is it after breast cancer treatment?",
    "completion": "Lymphedema is a common complication affecting about 20% of women after surgery or radiation for breast cancer."
  },
  {
    "prompt": "Which radiation type increases the risk of lymphedema more significantly?",
    "completion": "Regional lymph node radiation increases the risk of lymphedema more significantly than isolated radiation to the breast or chest wall (22% vs. 3%)."
  },
  {
    "prompt": "What treatments are available for lymphedema in breast cancer survivors?",
    "completion": "Treatment includes lymphatic drainage massage and compression sleeves."
  },
  {
    "prompt": "Which breast cancer treatments are associated with long-term cardiotoxicity?",
    "completion": "Chemotherapy, especially anthracyclines like doxorubicin, radiation therapy, trastuzumab, and cisplatin are associated with long-term cardiotoxicity."
  },
  {
    "prompt": "What cardiovascular complications can occur after breast cancer treatment?",
    "completion": "Complications include hypertension, arrhythmias, coronary artery disease, heart failure, thromboembolism, stroke, and pericardial disease."
  },
  {
    "prompt": "How does trastuzumab affect heart function?",
    "completion": "Trastuzumab can cause cardiotoxicity in up to 30% of HER2+ breast cancer survivors and increases the risk of heart failure, especially when combined with doxorubicin."
  },
  {
    "prompt": "What is the estimated incidence of radiation-induced cardiotoxicity?",
    "completion": "Radiation-induced cardiotoxicity occurs in an estimated 10–30% of patients 5 to 10 years after treatment."
  },
  {
    "prompt": "How does tamoxifen affect cardiovascular health?",
    "completion": "Tamoxifen increases the risk of venous thromboembolism in breast cancer survivors."
  },
  {
    "prompt": "What is the prevalence of fatigue in breast cancer survivors?",
    "completion": "Fatigue affects between 15–30% and up to 99% of breast cancer survivors."
  },
  {
    "prompt": "What factors contribute to persistent cancer-related fatigue?",
    "completion": "Factors include chronic inflammation, autonomic imbalance, HPA-axis dysfunction, and mitochondrial damage."
  },
  {
    "prompt": "How common is chemotherapy-induced peripheral neuropathy (CIPN) in BC survivors?",
    "completion": "About 58% of breast cancer survivors experience CIPN, often due to chemotherapy agents like docetaxel."
  },
  {
    "prompt": "What are the cognitive side effects of breast cancer treatment?",
    "completion": "Cognitive issues like memory loss, poor concentration, and executive dysfunction affect up to 35% of breast cancer survivors."
  },
  {
    "prompt": "Which treatments contribute to cognitive dysfunction in breast cancer patients?",
    "completion": "Chemotherapy, hormonal therapy, and anesthesia during surgery are linked to cognitive dysfunction."
  },
  {
    "prompt": "How prevalent is bone loss in breast cancer survivors?",
    "completion": "Almost 80% of breast cancer survivors experience some degree of bone loss."
  },
  {
    "prompt": "What is the impact of aromatase inhibitors on bone health?",
    "completion": "Aromatase inhibitors increase fracture risk nearly fivefold and worsen bone density."
  },
  {
    "prompt": "What musculoskeletal issues are common after breast cancer surgery?",
    "completion": "Common issues include rotator cuff disease, adhesive capsulitis, reduced shoulder mobility, and axillary web syndrome."
  },
  {
    "prompt": "Which treatments cause premature menopause and infertility in BC survivors?",
    "completion": "Chemotherapy and hormonal therapy, such as tamoxifen, are linked to premature menopause and infertility."
  },
  {
    "prompt": "What percentage of tamoxifen users experience vasomotor symptoms?",
    "completion": "Between 50% and 70% of tamoxifen users experience vasomotor symptoms like hot flashes."
  },
  {
    "prompt": "What sexual dysfunction symptoms are common in breast cancer survivors?",
    "completion": "Common symptoms include decreased libido, lubrication issues, anorgasmia, and painful intercourse."
  },
  {
    "prompt": "What factors contribute to sexual dysfunction in breast cancer survivors?",
    "completion": "Chemotherapy is a major cause, and complications from radiation or hormonal changes may also contribute."
  },
  {
    "prompt": "How do body image concerns affect breast cancer survivors?",
    "completion": "Body image concerns affect 31–67% of survivors, especially younger women, and impact mental health and intimate relationships."
  },
  {
    "prompt": "What mental health issues are prevalent in breast cancer survivors?",
    "completion": "Up to 25% experience depression or anxiety, and they are 60% more likely than the general population to develop mental health disorders."
  },
  {
    "prompt": "How common is fear of cancer recurrence in breast cancer survivors?",
    "completion": "More than 50% of breast cancer survivors experience fear of recurrence."
  },
  {
    "prompt": "Why is screening for distress and depression important in breast cancer survivors?",
    "completion": "It helps ensure survivors receive appropriate treatment or referrals for mental health issues."
  },



  {
    "prompt": "What is the rank of colorectal cancer among the most common cancers in the US?",
    "completion": "Colorectal cancer is the third most common cancer diagnosed in the US."
  },
  {
    "prompt": "How many colorectal cancer survivors are currently in the United States?",
    "completion": "There are currently over 1.4 million colorectal cancer survivors in the United States."
  },
  {
    "prompt": "What is the overall 5-year survival rate for colorectal cancer?",
    "completion": "The overall 5-year survival rate for colorectal cancer is 65%."
  },
  {
    "prompt": "What is the 5-year survival rate for early-stage colorectal cancer?",
    "completion": "The 5-year survival rate for early-stage colorectal cancer is 90%."
  },
  {
    "prompt": "What are the most common treatments for colorectal cancer?",
    "completion": "The most common treatments include surgical resection, with chemotherapy and/or radiation therapy used in neoadjuvant or adjuvant settings for advanced cases."
  },
  {
    "prompt": "What are some long-term side effects experienced by colorectal cancer survivors?",
    "completion": "Long-term side effects include bowel, bladder or sexual dysfunction, ostomy-related complications, neuropathy, and mental health issues."
  },
  {
    "prompt": "Which treatments are associated with fatigue in colorectal cancer survivors?",
    "completion": "Fatigue is associated with chemotherapy and radiation therapy."
  },
  {
    "prompt": "Which treatments cause pain in colorectal cancer survivors?",
    "completion": "Pain is associated with radiation therapy and surgery."
  },
  {
    "prompt": "What treatment is associated with cardiotoxicity in colorectal cancer?",
    "completion": "Cardiotoxicity is associated with chemotherapy."
  },
  {
    "prompt": "What gastrointestinal issues are common after colorectal cancer treatment?",
    "completion": "Common issues include bowel urgency, chronic diarrhea, fecal incontinence, and ostomy complications."
  },
  {
    "prompt": "Which treatments contribute to bowel urgency and chronic diarrhea in CRC survivors?",
    "completion": "Bowel urgency and chronic diarrhea are associated with radiation therapy and surgery."
  },
  {
    "prompt": "What are ostomy-related complications and what treatment causes them?",
    "completion": "Ostomy complications can occur after surgery for colorectal cancer."
  },
  {
    "prompt": "Which treatments lead to genitourinary issues in colorectal cancer survivors?",
    "completion": "Genitourinary problems like difficulty voiding or incontinence are caused by radiation therapy and surgery."
  },
  {
    "prompt": "What neurologic effects are associated with colorectal cancer treatment?",
    "completion": "Cognitive dysfunction and peripheral neuropathy are neurologic effects linked to chemotherapy."
  },
  {
    "prompt": "What are common psychosocial effects experienced by CRC survivors?",
    "completion": "Anxiety, distress, and depression are common psychosocial effects after chemotherapy, radiation, or surgery."
  },
  {
    "prompt": "What sexual dysfunction issues may arise after colorectal cancer treatment?",
    "completion": "Sexual dysfunctions such as decreased libido, erectile dysfunction, vaginal dryness, and dyspareunia may occur due to chemotherapy, radiation therapy, or surgery."
  },


  {
    "prompt": "What bowel symptoms are associated with radiation therapy in colorectal cancer survivors?",
    "completion": "Radiation therapy is associated with bowel frequency, urgency, fecal incontinence, radiation proctitis, and perianal irritation in colorectal cancer survivors."
  },
  {
    "prompt": "What percentage of colorectal cancer survivors experience chronic diarrhea?",
    "completion": "Approximately 50% of colorectal cancer survivors experience chronic diarrhea."
  },
  {
    "prompt": "Which surgeries increase the risk of bowel dysfunction in CRC survivors?",
    "completion": "Lower anterior resection and sphincter-saving surgery are linked to increased bowel dysfunction."
  },
  {
    "prompt": "How can bowel dysfunction impact other functions in CRC survivors?",
    "completion": "Severe bowel dysfunction may be associated with urinary dysfunction and reduced sexual satisfaction."
  },
  {
    "prompt": "What causes bladder dysfunction in colorectal cancer survivors?",
    "completion": "Bladder dysfunction can result from damage to sacral splanchnic nerves or preoperative radiation therapy, leading to symptoms like difficulty voiding and overflow incontinence."
  },
  {
    "prompt": "What are the primary symptoms of bladder dysfunction in CRC survivors?",
    "completion": "Symptoms include difficulty emptying the bladder, overflow incontinence, and loss of bladder fullness sensation."
  },
  {
    "prompt": "How common is long-term bladder dysfunction in CRC survivors?",
    "completion": "About one-third of CRC survivors experience long-term incontinence or difficulty with bladder emptying."
  },
  {
    "prompt": "What is the prevalence of urinary urgency or stress incontinence in CRC survivors?",
    "completion": "Up to 75% of colorectal cancer survivors may experience urinary urgency or urge-/stress-related incontinence."
  },
  {
    "prompt": "How common is sexual dysfunction in colorectal cancer survivors?",
    "completion": "Sexual dysfunction is reported in over one-third and up to two-thirds of colorectal cancer survivors."
  },
  {
    "prompt": "What are the causes of sexual dysfunction in CRC survivors?",
    "completion": "Sexual dysfunction may result from sacral plexus damage during surgery, autonomic nerve damage, presence of a stoma, or preoperative radiation."
  },
  {
    "prompt": "What sexual symptoms are experienced by CRC survivors?",
    "completion": "Symptoms include lack of libido, erectile dysfunction, ejaculatory problems in men, vaginal dryness, and painful intercourse in women."
  },
  {
    "prompt": "What are common complications associated with ostomies in CRC survivors?",
    "completion": "Common complications include peristomal skin irritation, leakage, odor, appliance noise, emotional distress, and impacts on sexual intimacy."
  },
  {
    "prompt": "How common are ostomies in sphincter-saving surgeries for CRC?",
    "completion": "Approximately 10% of patients undergoing sphincter-saving resections receive a temporary ileostomy."
  },
  {
    "prompt": "Which chemotherapy drug causes peripheral neuropathy in colorectal cancer survivors?",
    "completion": "Oxaliplatin, commonly used in advanced CRC, can cause chemotherapy-induced peripheral neuropathy."
  },
  {
    "prompt": "What percentage of CRC survivors experience oxaliplatin-induced grade 2 neuropathy?",
    "completion": "Around 77% of CRC survivors may experience grade 2 oxaliplatin-induced neuropathy."
  },
  {
    "prompt": "Is recovery from chemotherapy-induced neuropathy complete in CRC survivors?",
    "completion": "Less than 40% of patients recover fully from oxaliplatin-induced neuropathy, though symptoms are partially reversible for most."
  },
  {
    "prompt": "What cognitive domains are affected in CRC survivors?",
    "completion": "Processing speed, verbal memory, and attention/working memory are commonly affected."
  },
  {
    "prompt": "What is the prevalence of cognitive dysfunction among CRC survivors?",
    "completion": "Cognitive dysfunction affects between 36% and 52% of colorectal cancer survivors."
  },
  {
    "prompt": "What treatment increases cognitive dysfunction risk in CRC survivors?",
    "completion": "Adjuvant chemotherapy increases the risk of cognitive dysfunction."
  },
  {
    "prompt": "How prevalent is chronic pain in colorectal cancer survivors?",
    "completion": "Up to 25% of colorectal cancer survivors experience chronic pain."
  },
  {
    "prompt": "What skeletal complication can be caused by radiotherapy in CRC survivors?",
    "completion": "Radiotherapy can increase the risk of pelvic fractures."
  },
  {
    "prompt": "Which chemotherapy agent is associated with cardiotoxicity in CRC survivors?",
    "completion": "5-fluorouracil (5FU) is associated with cardiotoxicity in colorectal cancer survivors."
  },
  {
    "prompt": "What are symptoms of 5FU-induced cardiotoxicity?",
    "completion": "Symptoms include chest pain, myocardial infarction, arrhythmias, heart failure, cardiogenic shock, and sudden death."
  },
  {
    "prompt": "What increases the risk of cardiotoxicity from 5FU in CRC survivors?",
    "completion": "A history of coronary artery disease and prior mediastinal radiation increase the risk."
  },

  {
    "prompt": "What was the most frequent presenting symptom of breast cancer in the study?",
    "completion": "The most frequent presenting symptom was a breast lump, reported by 83% of women."
  },
  {
    "prompt": "What percentage of women reported nipple abnormalities as a presenting symptom?",
    "completion": "Nipple abnormalities were reported by 7% of women with breast cancer."
  },
  {
    "prompt": "How common was breast pain among presenting symptoms?",
    "completion": "Breast pain was reported by 6% of the women in the study."
  },
  {
    "prompt": "What were some of the non-breast symptoms reported in this study?",
    "completion": "Non-breast symptoms included back pain (1%) and weight loss (0.3%)."
  },
  {
    "prompt": "How did the diagnostic delay vary by symptom type?",
    "completion": "Women with non-lump symptoms or both lump and non-lump symptoms were more likely to wait 90 days or longer before seeking help, compared to those with breast lump only (15% and 20% vs. 7%)."
  },
  {
    "prompt": "Did differences in patient interval remain after adjusting for demographics?",
    "completion": "Yes, differences in the patient interval persisted even after adjusting for age and ethnicity."
  },
  {
    "prompt": "Was there significant variation in the primary care interval across symptom groups?",
    "completion": "There was little variation in the primary care interval for the majority of women, regardless of symptom type."
  },
  {
    "prompt": "What proportion of women had symptoms other than breast lump?",
    "completion": "About 1 in 6 women presented with symptoms other than a breast lump."
  },
  {
    "prompt": "What does the study suggest for public health campaigns?",
    "completion": "The study suggests that symptom awareness campaigns should place greater emphasis on breast symptoms other than breast lumps to reduce diagnostic delays."
  },
  {
    "prompt": "How were the presenting symptoms categorized in the study?",
    "completion": "Symptoms were categorized topographically into breast lump, non-lump breast symptoms (e.g., nipple abnormalities, breast pain), and non-breast symptoms (e.g., back pain, weight loss)."
  },


  {
    "prompt": "How many distinct symptoms were recorded in the study?",
    "completion": "A total of 56 distinct presenting symptoms were recorded among 2316 women with breast cancer."
  },
  {
    "prompt": "What was the average number of symptoms per woman in the study?",
    "completion": "On average, 1.1 symptoms were reported per woman in the study."
  },
  {
    "prompt": "What was the relative frequency of breast lump among symptomatic women?",
    "completion": "Breast lump was reported by 83.0% of the women (95% CI: 81.4%–84.5%)."
  },
  {
    "prompt": "What proportion of women with breast pain experienced delays greater than 90 days in seeking care?",
    "completion": "12% of women with breast pain had a patient interval greater than 90 days (95% CI: 8%–19%)."
  },
  {
    "prompt": "Which symptom had the longest median patient interval before presentation?",
    "completion": "Breast ulceration had the longest median patient interval before presentation at 122 days (IQR: 0–276)."
  },
  {
    "prompt": "Which symptom had the highest percentage of patients waiting more than 90 days before presentation?",
    "completion": "Breast ulceration had the highest proportion of delays over 90 days, affecting 56% of patients (95% CI: 27%–81%)."
  },
  {
    "prompt": "What was the median primary care interval for women presenting with a breast lump?",
    "completion": "The median primary care interval for women with a breast lump was 0 days (IQR: 0–0)."
  },
  {
    "prompt": "Which symptom had the highest percentage of patients requiring two or more pre-referral consultations?",
    "completion": "Chest pain had the highest rate of two or more pre-referral consultations, with 75% of cases."
  },
  {
    "prompt": "What percentage of women reporting nipple abnormalities waited more than 90 days to present?",
    "completion": "23% of women reporting nipple abnormalities experienced a patient interval over 90 days (95% CI: 17%–31%)."
  },
  {
    "prompt": "How many women in the study reported nipple abnormalities?",
    "completion": "A total of 158 women (6.8%, 95% CI: 5.9%–7.9%) reported nipple abnormalities."
  },
  {
    "prompt": "What was the diagnostic delay associated with axillary lumps?",
    "completion": "Women with axillary lumps had a median patient interval of 2.5 days (IQR: 0–12), with 0% waiting more than 90 days."
  },
  {
    "prompt": "Which non-breast symptoms showed high primary care intervals?",
    "completion": "Back pain and musculoskeletal pain had high primary care intervals, with median values of 21 days (IQR: 0–105) and 54 days (IQR: 0–187.5), respectively."
  },
  {
    "prompt": "What was the proportion of women with breast infection or inflammation needing two or more pre-referral consultations?",
    "completion": "60% of women with breast infection or inflammation had two or more pre-referral consultations."
  },
  {
    "prompt": "How many women reported musculoskeletal pain as a symptom?",
    "completion": "Fourteen women (0.6%, 95% CI: 0.4%–1.0%) reported musculoskeletal pain."
  },
  {
    "prompt": "Which symptom had the lowest pre-presentation patient interval median?",
    "completion": "Musculoskeletal pain had the shortest median patient interval at 0.5 days (IQR: 0–22)."
  },
  {
    "prompt": "What is the importance of these findings for breast cancer awareness campaigns?",
    "completion": "The findings highlight that many women with non-lump symptoms experience diagnostic delays, suggesting the need to broaden breast cancer awareness campaigns to include symptoms beyond breast lumps."
  },




  {
    "prompt": "How many women waited longer than 90 days before seeking medical help?",
    "completion": "A total of 164 women, or 9% of those with patient interval data, waited longer than 90 days before seeking help."
  },
  {
    "prompt": "Which symptoms were associated with the highest proportion of delays over 90 days before seeking help?",
    "completion": "Breast ulceration (50%), nipple abnormalities (23%), and breast infection or inflammation (21%) were associated with the highest delays."
  },
  {
    "prompt": "What percentage of women with breast ulceration waited more than 90 days before presenting?",
    "completion": "50% of women with breast ulceration had a patient interval exceeding 90 days."
  },
  {
    "prompt": "How common were primary care intervals of 90 days or more?",
    "completion": "Only 2% of women had a primary care interval of 90 days or more."
  },
  {
    "prompt": "What types of symptoms were associated with long primary care delays?",
    "completion": "Symptoms like non-specific breast abnormalities, back pain, musculoskeletal pain, chest pain, and fatigue or weakness were associated with prolonged primary care intervals."
  },
  {
    "prompt": "How do patient intervals compare with primary care intervals in terms of diagnostic delays?",
    "completion": "Patient intervals were more often prolonged, with 9% of women waiting over 90 days, compared to only 2% experiencing primary care delays of that length."
  },
  {
    "prompt": "What is the significance of delayed help-seeking for non-lump symptoms?",
    "completion": "Women with non-lump symptoms such as breast ulceration or nipple abnormalities were more likely to delay seeking help, highlighting the need for awareness beyond breast lumps."
  },

  {
    "prompt": "What proportion of women presented without a breast lump in this study?",
    "completion": "About 1 in 6 women with breast cancer presented without a breast lump, instead reporting a wide range of other symptoms."
  },
  {
    "prompt": "How did patient and primary care intervals differ across symptom groups?",
    "completion": "Patient intervals were longer for women with non-lump or both lump and non-lump symptoms compared to those with breast lump only, whereas primary care intervals were generally shorter and less variable."
  },
  {
    "prompt": "What is the significance of short primary care intervals in this study?",
    "completion": "The short primary care intervals suggest that delays in diagnosis primarily stem from patients' help-seeking behavior rather than inefficiencies in the healthcare system."
  },
  {
    "prompt": "What factors might explain longer patient intervals in the 'both lump and non-lump' symptom group?",
    "completion": "One possibility is that the presence of non-lump symptoms may lead women to normalize or misinterpret a breast lump, delaying help-seeking."
  },
  {
    "prompt": "Why are findings from this study considered generalizable despite the healthcare setting?",
    "completion": "Because the main source of diagnostic delay was the patient interval, which is less influenced by the publicly funded healthcare system context, the findings are considered relevant across different healthcare settings."
  },
  {
    "prompt": "What are some limitations of the symptom data used in this study?",
    "completion": "Limitations include reliance on patient recall, potential under-capture of non-specific symptoms, missing data for some outcomes, and lack of socioeconomic variables like deprivation or health literacy."
  },
  {
    "prompt": "Why might awareness campaigns need to shift focus according to this study?",
    "completion": "Because many women with non-lump symptoms delay help-seeking, campaigns should broaden awareness beyond just breast lumps to include other potential symptoms like nipple abnormalities or breast ulceration."
  },
  {
    "prompt": "What challenges exist in diagnosing breast cancer from non-breast symptoms?",
    "completion": "Non-breast symptoms like back pain or breathlessness are less specific and often appear in late-stage disease, making early detection and effective triage more difficult."
  },
  {
    "prompt": "What does the study recommend for future awareness campaigns?",
    "completion": "The study supports expanding symptom awareness to include non-lump breast symptoms and considering their predictive value for breast cancer."
  },
  {
    "prompt": "How does this study improve on previous research?",
    "completion": "It is the largest and most detailed study to date examining the association between a wide range of presenting symptoms and diagnostic delays in breast cancer."
  },
  {
    "prompt": "What is the potential explanation for delayed presentation even when a lump is present along with non-lump symptoms?",
    "completion": "Women may misinterpret or downplay a breast lump if it occurs alongside other non-lump symptoms, leading to delayed help-seeking."
  },
  {
    "prompt": "What role could prospective designs play in future studies?",
    "completion": "Prospective studies could clarify the time sequence between symptom onset and diagnostic intervals, though they may face logistical and sample size constraints."
  },
  {
    "prompt": "What future diagnostic strategies are proposed for handling non-specific symptoms?",
    "completion": "Initiatives like the Danish 'three-legged strategy' and England's ACE program may help improve diagnosis in patients presenting with vague or non-specific symptoms."
  },

  {
    "prompt": "What is the most common cancer diagnosed in women worldwide?",
    "completion": "Breast cancer is the most common cancer diagnosed in women worldwide."
  },
  {
    "prompt": "Where in the breast does cancer most commonly arise?",
    "completion": "Breast cancer most commonly arises in the ductal epithelium, known as ductal carcinoma."
  },
  {
    "prompt": "What is lobular carcinoma?",
    "completion": "Lobular carcinoma is a type of breast cancer that develops in the lobules of the breast."
  },
  {
    "prompt": "What are the structural components of the breast?",
    "completion": "The breast contains lobules, lobes, acini, lactiferous ducts, and is supported by Cooper's ligaments."
  },
  {
    "prompt": "What are some common presenting symptoms of breast cancer in developing countries?",
    "completion": "In developing countries, a breast mass or abnormal nipple discharge are often the initial symptoms of breast cancer."
  },
  {
    "prompt": "How is breast cancer diagnosed?",
    "completion": "Breast cancer is diagnosed through physical examination, breast imaging, and tissue biopsy."
  },
  {
    "prompt": "What are the major treatment options for breast cancer?",
    "completion": "Treatment options include surgery, chemotherapy, radiation, hormonal therapy, and immunotherapy."
  },
  {
    "prompt": "What factors guide individualized treatment decisions for breast cancer?",
    "completion": "Histology, stage, tumor markers, and genetic abnormalities guide individualized treatment decisions."
  },
  {
    "prompt": "How does age affect breast cancer risk?",
    "completion": "Breast cancer risk increases with advancing age."
  },
  {
    "prompt": "How do BRCA1 and BRCA2 genes relate to breast cancer?",
    "completion": "Mutations in BRCA1 and BRCA2 are major genetic factors increasing susceptibility to breast cancer."
  },
  {
    "prompt": "What reproductive milestones are associated with increased breast cancer risk?",
    "completion": "Early menarche (<12 years), late menopause (>55 years), nulliparity, and first childbirth after age 30 increase breast cancer risk."
  },
  {
    "prompt": "What hormonal factors are associated with breast cancer risk?",
    "completion": "Use of estrogen and progesterone, whether for contraception or hormone replacement, is associated with increased risk."
  },
  {
    "prompt": "How does family history affect breast cancer risk?",
    "completion": "First-degree relatives of breast cancer patients have a 2- to 3-fold increased risk of developing the disease."
  },
  {
    "prompt": "What is lobular carcinoma in situ (LCIS) and why is it important?",
    "completion": "LCIS is a histologic abnormality that indicates an increased risk for developing invasive breast cancer."
  },
  {
    "prompt": "Which lifestyle and environmental factors are linked to higher breast cancer risk?",
    "completion": "Radiation exposure, obesity, alcohol consumption, and environmental pollutants are linked to increased breast cancer risk."
  },



  {
    "prompt": "What percentage of global cancer cases in 2020 were due to invasive breast cancer?",
    "completion": "Invasive breast cancer accounted for approximately 11.7% of new cancer cases worldwide in 2020."
  },
  {
    "prompt": "What is the lifetime risk of breast cancer in women and men in the US?",
    "completion": "In the US, 1 in 8 women and 1 in 1000 men will develop breast cancer during their lifetime."
  },
  {
    "prompt": "At what age does the incidence of breast cancer peak in women?",
    "completion": "The incidence of breast cancer peaks at 421.3 cases per 100,000 in women aged 75 to 79 years."
  },
  {
    "prompt": "What is the median age at diagnosis for breast cancer in women?",
    "completion": "The median age of women at the time of breast cancer diagnosis is 61 years."
  },
  {
    "prompt": "How much has breast cancer mortality decreased in the US since 1980?",
    "completion": "Breast cancer mortality in the US has decreased by 43% from 1980 to 2020."
  },
  {
    "prompt": "Which racial group has the highest breast cancer incidence in the US?",
    "completion": "Non-Hispanic white women have the highest incidence of breast cancer at 128.1 per 100,000."
  },
  {
    "prompt": "Which racial group has the highest mortality rate despite lower incidence?",
    "completion": "African American women have a higher mortality rate despite a lower incidence compared to non-Hispanic whites."
  },
  {
    "prompt": "What percentage of breast cancer cases are due to identifiable genetic mutations?",
    "completion": "Only 5% to 10% of breast cancer cases are due to identifiable genetic mutations such as BRCA1 and BRCA2."
  },
  {
    "prompt": "What are the four molecular subtypes of breast cancer?",
    "completion": "The four molecular subtypes are Luminal A, Luminal B, HER-2 enriched, and Basal-like."
  },
  {
    "prompt": "Which molecular subtype of breast cancer is associated with the worst prognosis?",
    "completion": "Basal-like breast cancer, which is triple-negative, tends to have the worst prognosis and survival rates."
  },
  {
    "prompt": "Which breast cancer subtype benefits most from targeted anti-HER2 therapy?",
    "completion": "HER-2 enriched tumors benefit significantly from targeted therapy such as trastuzumab."
  },
  {
    "prompt": "What is the most common histologic subtype of invasive breast cancer?",
    "completion": "Invasive ductal carcinoma is the most common histologic subtype, accounting for 50% to 75% of cases."
  },
  {
    "prompt": "What are the distinguishing features of invasive lobular carcinoma?",
    "completion": "Invasive lobular carcinoma tends to grow in a single-file pattern, often remains clinically occult, and is E-cadherin negative."
  },
  {
    "prompt": "What histologic subtype of breast cancer is associated with mucin production?",
    "completion": "Mucinous (colloid) carcinoma is characterized by mucin production and typically occurs in older women."
  },
  {
    "prompt": "Which breast cancer subtype is seen more frequently in BRCA mutation carriers?",
    "completion": "Medullary carcinoma is more common in BRCA mutation carriers and tends to be aggressive."
  },
  {
    "prompt": "What percentage of breast cancers are tubular carcinomas?",
    "completion": "Tubular carcinoma accounts for 1% to 2% of all breast cancers."
  },
  {
    "prompt": "What histological markers are routinely assessed in breast cancer specimens?",
    "completion": "Hormone receptors (estrogen and progesterone), HER-2 receptors, Ki-67 index, and tumor grade are routinely assessed."
  },


  {
    "prompt": "According to ACOG, how often should women aged 25 to 39 undergo clinical breast examinations?",
    "completion": "ACOG recommends that women aged 25 to 39 may undergo clinical breast examinations every 1 to 3 years."
  },
  {
    "prompt": "What are the common physical signs of advanced breast cancer?",
    "completion": "Common physical signs of advanced breast cancer include peau d'orange, ulceration, axillary lymphadenopathy, and signs of distant metastasis."
  },
  {
    "prompt": "What is peau d’orange and what does it indicate?",
    "completion": "Peau d'orange refers to skin thickening and dimpling resembling orange peel and may indicate lymphatic obstruction in advanced breast cancer."
  },
  {
    "prompt": "How often should high-risk or symptomatic women receive clinical breast examinations?",
    "completion": "High-risk or symptomatic women should always receive a clinical breast examination, regardless of age."
  },
  {
    "prompt": "What is the role of physical examination in breast cancer assessment?",
    "completion": "Physical examination is a vital component of clinical breast cancer assessment and includes inspection and palpation in multiple positions with evaluation of lymph nodes."
  },
  {
    "prompt": "Which breast cancer subtype can mimic a breast abscess clinically?",
    "completion": "Inflammatory breast cancer may mimic a breast abscess and presents with swelling, redness, and local inflammatory signs."
  },
  {
    "prompt": "Is breast pain a common symptom of breast cancer?",
    "completion": "Breast pain is an uncommon symptom, occurring in only about 5% of breast cancer cases."
  },
  {
    "prompt": "What imaging modality is most commonly used for breast cancer screening?",
    "completion": "Mammography is the most commonly used modality for breast cancer screening and diagnosis."
  },
  {
    "prompt": "What are the limitations of mammography?",
    "completion": "Mammography is less effective in women with dense breast tissue, younger patients, and those who cannot tolerate breast compression."
  },
  {
    "prompt": "When is breast MRI indicated for evaluation?",
    "completion": "MRI is indicated for evaluating axillary lymph node disease, occult primary malignancy, Paget disease, multifocal or bilateral cancers, and high-risk screening or treatment response."
  },
  {
    "prompt": "What is BI-RADS used for?",
    "completion": "The BI-RADS system classifies breast imaging findings based on their malignancy risk and provides guidance for management decisions."
  },
  {
    "prompt": "What imaging options are preferred for women with dense breasts?",
    "completion": "Breast ultrasound and MRI are preferred in women with dense breast tissue where mammography may be limited."
  },
  {
    "prompt": "How does diagnostic mammography differ from screening mammography?",
    "completion": "Diagnostic mammography uses higher resolution and multiple views to further evaluate abnormalities seen on screening mammograms."
  },
  {
    "prompt": "What are some abnormal findings on screening mammography?",
    "completion": "Abnormal findings include mass lesions, calcifications, and architectural distortions."
  },



  {
    "prompt": "What is the preferred biopsy method for a suspicious breast lesion?",
    "completion": "Stereotactic core needle biopsy is the preferred method for sampling suspicious breast lesions."
  },
  {
    "prompt": "Why is core needle biopsy preferred over fine needle aspiration in breast cancer?",
    "completion": "Core needle biopsy provides more tissue for histopathologic evaluation and receptor testing, making it superior to fine needle aspiration."
  },
  {
    "prompt": "What is the standard biopsy method for clinically positive lymph nodes?",
    "completion": "An ultrasound-guided core needle biopsy is used to sample clinically positive regional lymph nodes."
  },
  {
    "prompt": "Why are radiographic markers used during biopsy?",
    "completion": "Radiographic markers are placed to localize the biopsy site for future identification during surgery or imaging."
  },
  {
    "prompt": "What tests must be performed on biopsy breast tissue samples?",
    "completion": "Biopsy specimens must undergo histopathologic evaluation including testing for estrogen receptors, progesterone receptors, and HER2."
  },
  {
    "prompt": "Are routine systemic imaging tests recommended for all operable breast cancer patients?",
    "completion": "No, systemic imaging is not routinely recommended unless the patient has symptoms suggestive of metastasis."
  },
  {
    "prompt": "What imaging studies are used if metastatic symptoms are present?",
    "completion": "MRI of the brain, chest CT, bone scan, or CT of the abdomen and pelvis may be performed if indicated by symptoms."
  },
  {
    "prompt": "When are baseline blood tests indicated in breast cancer patients?",
    "completion": "Baseline blood tests, including complete blood count and liver function tests, are indicated if neoadjuvant chemotherapy is planned."
  },
  {
    "prompt": "What staging imaging is used in clinically advanced breast cancer?",
    "completion": "For advanced disease, CT of the chest, abdomen, and pelvis, along with a bone scan or FDG-PET, is commonly used."
  },
  {
    "prompt": "Which clinical signs suggest advanced breast cancer requiring systemic imaging?",
    "completion": "Inflammatory breast cancer, chest wall or skin involvement, and bulky axillary lymphadenopathy are signs that may warrant systemic imaging."
  },


  {
    "prompt": "What defines early breast cancer in terms of tumor size and lymph node status?",
    "completion": "Early breast cancer includes tumors smaller than 5 cm in size without clinically positive lymph nodes."
  },
  {
    "prompt": "What are the main surgical options for early breast cancer?",
    "completion": "Surgical options for early breast cancer include breast conservation surgery (partial mastectomy or lumpectomy) and total mastectomy."
  },
  {
    "prompt": "When is completion axillary dissection or radiation indicated after sentinel lymph node biopsy?",
    "completion": "Completion axillary dissection or axillary radiation is indicated if more than 3 axillary lymph nodes are microscopically positive or if there is extranodal extension."
  },
  {
    "prompt": "How is chemotherapy recommended for hormone receptor-positive early breast cancer patients?",
    "completion": "Chemotherapy for hormone receptor-positive early breast cancer is guided by genomic risk stratification, with high-risk patients benefiting from chemotherapy in addition to hormonal therapy."
  },
  {
    "prompt": "Which breast cancer patients should receive anti-HER2-directed therapy?",
    "completion": "All HER2-positive patients with tumors larger than 1 cm should receive anti-HER2-directed therapy."
  },
  {
    "prompt": "What chemotherapy approach is favored for early-stage triple-negative and HER2-positive tumors?",
    "completion": "Up-front (neoadjuvant) chemotherapy is increasingly used in early-stage triple-negative and HER2-positive tumors to allow response assessment and increase breast conservation rates."
  },
  {
    "prompt": "What defines locally advanced breast cancer (LABC)?",
    "completion": "LABC primarily includes tumors larger than 5 cm or those with clinically positive lymph nodes."
  },
  {
    "prompt": "What is the typical management strategy for LABC patients?",
    "completion": "Most LABC patients receive neoadjuvant therapy followed by surgery and radiation therapy."
  },
  {
    "prompt": "Why are radiographically detectable markers placed before neoadjuvant chemotherapy in LABC?",
    "completion": "Markers are placed to localize the primary tumor and lymph nodes because tumors can shrink or disappear after chemotherapy."
  },
  {
    "prompt": "What are contraindications to breast conservation surgery in LABC?",
    "completion": "Contraindications include large tumors, chest wall or skin involvement, multifocal disease, inability to receive radiation, and unfavorable tumor-to-breast size ratio."
  },
  {
    "prompt": "What is the axillary management for patients with clinically positive axilla at LABC diagnosis?",
    "completion": "An axillary dissection is always performed regardless of response to neoadjuvant chemotherapy."
  },
  {
    "prompt": "How is axillary management handled in clinically negative axilla at LABC diagnosis?",
    "completion": "Sentinel lymph node biopsy is performed during surgery, and if residual disease is present, completion axillary dissection or radiation is indicated."
  },
  {
    "prompt": "What is the role of radiation therapy after surgery in early breast cancer and LABC?",
    "completion": "Radiation is mandatory after breast conservation surgery and indicated after mastectomy in cases such as large tumors, skin involvement, multifocal tumors, or multiple positive lymph nodes."
  },
  {
    "prompt": "When is hormonal therapy indicated in breast cancer treatment?",
    "completion": "Hormonal therapy with anti-estrogens or aromatase inhibitors is indicated in all hormone receptor-positive breast cancer patients."
  },
  {
    "prompt": "What are the goals of neoadjuvant chemotherapy in LABC?",
    "completion": "The goals are to reduce tumor size, eradicate micrometastatic disease, and assess tumor biology based on chemotherapy responsiveness."
  },
  {
    "prompt": "How is systemic chemotherapy tailored in breast cancer?",
    "completion": "Systemic chemotherapy regimens vary based on tumor pathology (hormone receptor, HER2 status, triple-negative), patient age, physical status, and local resources."
  },



  {
    "prompt": "What is the primary treatment approach for metastatic breast cancer?",
    "completion": "Metastatic breast cancer is managed primarily with systemic therapy, including chemotherapy, targeted therapy, immunotherapy, and hormonal therapy, depending on the molecular profile and patient fitness."
  },
  {
    "prompt": "When is surgery recommended in metastatic breast cancer?",
    "completion": "Surgery is generally not recommended in metastatic breast cancer except for symptom control and palliative therapy."
  },
  {
    "prompt": "What role does radiation therapy play in metastatic breast cancer?",
    "completion": "Palliative radiation is used to control bulky primary tumors and metastases to the brain, bone, and lung."
  },
  {
    "prompt": "Name three common conditions in the differential diagnosis of breast cancer.",
    "completion": "Mastitis or breast abscess, fat necrosis, and fibroadenoma are common conditions in the differential diagnosis of breast cancer."
  },
  {
    "prompt": "How can mastitis be distinguished from inflammatory breast cancer?",
    "completion": "Inflammation or cellulitis that does not respond to antibiotics should be evaluated further to rule out inflammatory breast cancer."
  },
  {
    "prompt": "What is fat necrosis and how does it relate to breast cancer diagnosis?",
    "completion": "Fat necrosis is a benign condition caused by trauma, which can harden and mimic a breast cancer mass."
  },
  {
    "prompt": "What is the typical surgical approach for tumors smaller than 5 cm in breast cancer?",
    "completion": "Breast conservation surgery, such as partial mastectomy or lumpectomy, is typically performed for tumors smaller than 5 cm."
  },
  {
    "prompt": "When is mastectomy indicated in breast cancer treatment?",
    "completion": "Mastectomy is indicated for large primary tumors, tumors invading the skin or chest wall, multifocal cancers, inflammatory breast cancer, or when patients cannot undergo radiation."
  },
  {
    "prompt": "What is the role of sentinel lymph node biopsy in breast cancer surgery?",
    "completion": "Sentinel lymph node biopsy is a vital staging procedure performed in patients with clinically negative axilla to assess lymph node involvement."
  },
  {
    "prompt": "When can axillary lymph node dissection be safely avoided?",
    "completion": "Axillary lymph node dissection can be safely avoided in patients with 1 to 3 positive sentinel lymph nodes without gross extranodal extension."
  },
  {
    "prompt": "Describe the procedure and purpose of partial mastectomy or lumpectomy.",
    "completion": "Partial mastectomy or lumpectomy involves excision of a portion of breast tissue with healthy margins, aiming to conserve most of the breast while removing the tumor."
  },
  {
    "prompt": "How are nonpalpable breast lesions localized before surgery?",
    "completion": "Nonpalpable lesions are localized preoperatively using wire or radioactive seed localization to ensure complete tumor removal."
  },


  {
    "prompt": "What does a simple mastectomy involve?",
    "completion": "A simple mastectomy involves excision of the entire breast and nipple-areola complex along with the underlying pectoralis major fascia. The amount of skin preserved varies depending on reconstruction plans."
  },
  {
    "prompt": "How does a nipple-sparing mastectomy differ from a simple mastectomy?",
    "completion": "A nipple-sparing mastectomy spares the nipple-areolar complex while removing the breast tissue through a small circumareolar incision, resulting in superior cosmetic outcomes but with a slightly increased oncologic risk compared to simple mastectomy."
  },
  {
    "prompt": "What is a modified radical mastectomy?",
    "completion": "A modified radical mastectomy combines the removal of the entire breast (simple mastectomy) with axillary lymph node dissection via an extended mastectomy incision."
  },
  {
    "prompt": "Is radical mastectomy commonly performed today?",
    "completion": "No, radical mastectomy, which includes removal of pectoral muscles and nerves, is seldom performed nowadays."
  },
  {
    "prompt": "Describe the procedure of axillary sentinel lymph node biopsy.",
    "completion": "In axillary sentinel lymph node biopsy, a radiotracer or blue dye is injected near the tumor, and 1 to 3 lymph nodes with the highest uptake or blue color in the axilla are removed for pathological examination."
  },
  {
    "prompt": "How is axillary lymph node dissection performed?",
    "completion": "Axillary lymph node dissection involves removal of fibrofatty and lymphoid tissue in axillary levels 2 and 3, while preserving the long thoracic and thoracodorsal nerves."
  },
  {
    "prompt": "Where are the axillary lymph nodes located in relation to the pectoralis minor muscle?",
    "completion": "Axillary lymph nodes are divided into three levels based on their location relative to the pectoralis minor muscle."
  },
  {
    "prompt": "Can the same incision be used for lumpectomy and sentinel lymph node biopsy?",
    "completion": "Sometimes, the same incision can be used for both lumpectomy and sentinel lymph node biopsy; otherwise, a separate incision at the axillary hairline may be required."
  },

  {
    "prompt": "What is the role of radiation therapy in early-stage breast cancer?",
    "completion": "Radiation therapy primarily serves as adjuvant treatment in early-stage breast cancer, reducing the risk of breast recurrence by approximately 50%, though it has not been shown to improve overall survival."
  },
  {
    "prompt": "What are the common modalities used to deliver adjuvant radiotherapy in breast cancer?",
    "completion": "Adjuvant radiotherapy can be delivered using external beam radiation, brachytherapy, or a combination of both."
  },
  {
    "prompt": "What is Accelerated Partial Breast Irradiation (APBI) and who is it suitable for?",
    "completion": "APBI is a technique delivering targeted radiation to the surgical cavity over approximately 1 week, suitable for select patients as per ASTRO guidelines; it can be delivered via brachytherapy with implantable catheters or external beam radiation using surgical clips or markers for planning."
  },
  {
    "prompt": "What are the advantages and limitations of APBI compared to whole breast radiation?",
    "completion": "APBI offers a shorter treatment duration (about 1 week) compared to whole breast radiation (3 to 6 weeks), but catheter-based APBI may require additional surgery and possible treatment delays."
  },
  {
    "prompt": "Describe the whole breast radiation therapy (WBRT) technique and dosing.",
    "completion": "WBRT involves 3D conformal radiation covering all visible breast tissue, typically dosed between 40.05 to 50.4 Gy over 15 to 25 fractions, aiming to minimize dose to the ipsilateral lung and heart."
  },
  {
    "prompt": "What is the purpose of a radiation boost in breast cancer treatment?",
    "completion": "A radiation boost is an additional dose (10 to 16 Gy) delivered to the surgical cavity after WBRT to improve local control and reduce recurrence, especially beneficial for women under 60 years old."
  },
  {
    "prompt": "What are the potential risks associated with a radiation boost?",
    "completion": "Radiation boost increases the risk of breast fibrosis, which may affect cosmetic outcomes, with severe fibrosis rates reported at 4.4% compared to 1.6% without the boost."
  },
  {
    "prompt": "When is post-mastectomy radiation therapy (PMRT) indicated?",
    "completion": "PMRT is indicated in patients with nodal disease after axillary staging, positive surgical margins, tumors larger than 5 cm, and high-risk pathological features such as central or medial tumors ≥2 cm with lymphovascular invasion, grade 3, or hormone receptor negativity."
  },
  {
    "prompt": "What areas are covered in comprehensive nodal irradiation (CNI)?",
    "completion": "CNI covers lymphatic drainage areas including axillary levels I to III, supraclavicular nodes, and internal mammary nodes, and can be included with WBRT or PMRT."
  },
  {
    "prompt": "What challenges are associated with comprehensive nodal irradiation?",
    "completion": "CNI is technically challenging due to the need for multiple radiation fields, increased dose exposure to lungs and heart, especially when treating the left breast, and may increase risks of lymphedema and radiation pneumonitis."
  },
  {
    "prompt": "How does comprehensive nodal irradiation compare to axillary lymph node dissection in terms of axillary control?",
    "completion": "CNI has similar axillary control rates compared to axillary lymph node dissection in patients with 1 to 3 positive nodes."
  },
  {
    "prompt": "What techniques can help minimize heart dose during radiation therapy for left-sided breast cancer?",
    "completion": "Techniques such as deep inspiratory breath hold (DIBH) and intensity-modulated radiation therapy (IMRT) can reduce heart exposure during radiation."
  },



  {
    "prompt": "What is intensity-modulated radiation therapy (IMRT) in breast cancer treatment?",
    "completion": "IMRT is an advanced radiation technique that delivers radiation more precisely to the breast tissue and is used as an alternative to conventional 3D planning, especially when heart dose constraints cannot be met."
  },
  {
    "prompt": "What are the benefits of IMRT compared to conventional 3D or 2D radiation planning?",
    "completion": "IMRT significantly reduces the incidence of grade 2 or higher radiation dermatitis compared to conventional 3D or 2D planning, with no differences observed in recurrence or survival."
  },
  {
    "prompt": "What long-term cardiac risks are associated with breast irradiation?",
    "completion": "Breast irradiation increases the risk of major coronary events due to accelerated atherosclerosis of the coronary arteries, with risk rising linearly by 7.4% per gray of radiation dose to the heart."
  },
  {
    "prompt": "Which patients are at higher risk for cardiac toxicity from breast radiation therapy?",
    "completion": "Women with preexisting cardiac risk factors have an even higher risk of radiation-induced cardiac toxicity."
  },
  {
    "prompt": "What is radiation pneumonitis and how common is it after breast radiotherapy?",
    "completion": "Radiation pneumonitis is inflammation of the lung caused by radiation, occurring in approximately 0.8% to 2.9% of patients after breast radiotherapy, typically within one year post-treatment."
  },
  {
    "prompt": "What factors increase the risk of radiation pneumonitis in breast cancer patients?",
    "completion": "Higher lung volume irradiated, comprehensive nodal radiation, and concurrent use of taxane chemotherapy drugs such as paclitaxel increase the risk of radiation pneumonitis."
  },
  {
    "prompt": "How can radiation pneumonitis be prevented during breast cancer radiotherapy?",
    "completion": "Careful radiation planning and adherence to lung dose constraints are the most effective measures to prevent radiation pneumonitis."
  },
  {
    "prompt": "What is breast fibrosis and when does it typically occur after radiation therapy?",
    "completion": "Breast fibrosis is a condition characterized by breast shrinkage, hardening, pain, and poor wound healing, typically occurring 4 to 12 months after adjuvant radiotherapy."
  },
  {
    "prompt": "What factors influence the risk of moderate to severe breast fibrosis after radiation?",
    "completion": "Risk factors include total breast radiation dose, beam energy, dose heterogeneity, radiation boost to the surgical cavity, and chemotherapy."
  },
  {
    "prompt": "What preventive measures can reduce the risk of breast fibrosis after radiation therapy?",
    "completion": "Preventive measures include weighing the benefits of radiation boost, lowering beam energy, limiting dose hotspots to less than 107% of prescribed dose, and use of pentoxifylline with vitamin E for six months post-radiation in high-risk patients."
  },
  {
    "prompt": "Is breast fibrosis reversible, and how is it managed?",
    "completion": "Breast fibrosis is mostly irreversible once developed; management is symptomatic, including NSAIDs, SNRIs, and anticonvulsants such as gabapentin."
  },



  {
    "prompt": "What is lymphedema in breast cancer patients, and when does it typically occur?",
    "completion": "Lymphedema is progressive swelling of the upper extremity that may occur about 6 months after radiation therapy in breast cancer patients."
  },
  {
    "prompt": "What are common symptoms of lymphedema after breast cancer treatment?",
    "completion": "Symptoms include increased arm girth, swelling, heaviness, poor wound healing, and increased risk of infection."
  },
  {
    "prompt": "What factors increase the risk of lymphedema in breast cancer patients?",
    "completion": "Risk factors include the number of lymph nodes removed, body mass index, and the extent of irradiated lymphatics."
  },
  {
    "prompt": "How does the risk of lymphedema compare between sentinel lymph node biopsy and full axillary dissection?",
    "completion": "Sentinel lymph node biopsy has a 5.6% risk of lymphedema, whereas full axillary dissection carries a higher risk of 19.9%."
  },
  {
    "prompt": "What was the 5-year lymphedema rate in the AMAROS trial for axillary dissection versus regional nodal radiation?",
    "completion": "The AMAROS trial reported a 5-year lymphedema rate of 25% in patients undergoing axillary dissection and 12% in those receiving regional nodal radiation alone."
  },
  {
    "prompt": "What preventive measures may help reduce lymphedema risk after breast cancer treatment?",
    "completion": "Weight-bearing exercise and maintaining a healthy body weight are suggested preventive measures."
  },
  {
    "prompt": "How is lymphedema managed in breast cancer patients?",
    "completion": "Management includes fitted compression garments, arm elevation, and exercise."
  },
  {
    "prompt": "What is brachial plexopathy in the context of breast cancer radiotherapy?",
    "completion": "Brachial plexopathy is nerve injury causing hand and arm paresthesia, weakness, and shoulder pain, typically occurring 8 to 12 months after regional nodal radiation."
  },
  {
    "prompt": "What is the incidence and primary prevention strategy for brachial plexopathy in breast cancer patients?",
    "completion": "It affects approximately 1% of patients, and prevention involves limiting radiation doses to below 50 Gy."
  },
  {
    "prompt": "How is brachial plexopathy treated in breast cancer patients?",
    "completion": "Treatment includes gabapentin and physical therapy to manage symptoms."
  },
  {
    "prompt": "How common are rib fractures as a complication of breast radiotherapy?",
    "completion": "Rib fractures are rare, occurring in approximately 0.3% to 1.8% of patients."
  },
  {
    "prompt": "What factors increase the risk of rib fractures after breast radiotherapy?",
    "completion": "Risk is associated with the use of lower energy radiation beams and higher radiation doses."
  },
  {
    "prompt": "What is the typical treatment approach for rib fractures caused by breast radiation?",
    "completion": "Treatment is generally conservative and supportive."
  },
  {
    "prompt": "What is the risk of secondary malignancies following breast cancer radiotherapy?",
    "completion": "The absolute risk of developing secondary malignancies is low, around 1% to 2% at 10 years after radiotherapy."
  },
  {
    "prompt": "Which secondary cancers are patients at increased risk for after breast radiation therapy?",
    "completion": "Patients have an increased risk of non-breast cancers, including sarcomas, lung cancer, and esophageal cancer."
  },
  {
    "prompt": "What factors influence the risk of radiation-induced secondary malignancies?",
    "completion": "Age, gender, radiation field size, and radiation dose are important risk factors."
  },


  {
    "prompt": "What types of systemic therapies are used in breast cancer management?",
    "completion": "Systemic therapies used in breast cancer management include chemotherapy, hormone therapy, immunotherapy, and targeted therapy."
  },
  {
    "prompt": "In which breast cancer subtypes is cytotoxic chemotherapy most effective?",
    "completion": "Cytotoxic chemotherapy is most effective in high-grade, poorly differentiated tumors such as triple-negative and HER2-positive breast cancers."
  },
  {
    "prompt": "What are some early and modern chemotherapy regimens used in breast cancer treatment?",
    "completion": "Early regimens included CMF (cyclophosphamide, methotrexate, and 5-fluorouracil), while modern regimens often use anthracyclines (doxorubicin or epirubicin) and taxanes, such as TAC (docetaxel, adriamycin, and cyclophosphamide)."
  },
  {
    "prompt": "How is chemotherapy recommended for triple-negative and HER2-positive breast tumors?",
    "completion": "Adjuvant chemotherapy is recommended for most patients with triple-negative and HER2-positive tumors larger than T1 stage."
  },
  {
    "prompt": "What role does neoadjuvant chemotherapy play in breast cancer treatment?",
    "completion": "Neoadjuvant chemotherapy is increasingly used in triple-negative and HER2-positive tumors to improve compliance, downstage tumors, and assess tumor biological response."
  },
  {
    "prompt": "What is anti-HER2 therapy and when is it used?",
    "completion": "Anti-HER2 therapy targets HER2/neu overexpression found in about 17% of breast cancers. Trastuzumab is the first approved monoclonal antibody that reduces recurrence and death risks when combined with chemotherapy in HER2-positive early breast cancer."
  },
  {
    "prompt": "What benefits does dual HER2 blockade with trastuzumab and pertuzumab provide?",
    "completion": "Dual HER2 blockade improves response rates in HER2-positive breast cancer compared to trastuzumab alone."
  },
  {
    "prompt": "What are PARP inhibitors, and who benefits from them?",
    "completion": "PARP inhibitors like olaparib and talazoparib inhibit DNA repair enzymes and are indicated in HER2-negative breast cancer patients with BRCA mutations, primarily in the adjuvant setting."
  },
  {
    "prompt": "How do CDK4/6 inhibitors work and for which breast cancer patients are they indicated?",
    "completion": "CDK4/6 inhibitors (e.g., palbociclib) block proteins that promote cell division, promoting tumor cell death. They are used in metastatic HR-positive, HER2-negative tumors and selected early HR-positive tumors."
  },
  {
    "prompt": "What is the mechanism and indication for immune checkpoint inhibitors in breast cancer?",
    "completion": "Immune checkpoint inhibitors such as pembrolizumab and nivolumab act on the PD-1/PD-L1 pathway to activate the immune system and are currently indicated in triple-negative breast cancer, especially in the metastatic setting."
  },
  {
    "prompt": "What hormonal treatments are used for HR-positive breast cancers?",
    "completion": "Selective estrogen receptor modulators (e.g., tamoxifen) and aromatase inhibitors (e.g., exemestane, letrozole) are used in HR-positive breast cancers, with modulators mainly for premenopausal women and aromatase inhibitors for postmenopausal women."
  },
  {
    "prompt": "What additional hormonal therapy options may benefit premenopausal women with breast cancer?",
    "completion": "Premenopausal women may benefit from oophorectomy or chemical ovarian suppression using GnRH antagonists to reduce estrogen production."
  },
  {
    "prompt": "For how long is hormonal therapy typically indicated in breast cancer patients?",
    "completion": "Hormonal therapy is usually indicated for 5 to 10 years to reduce the risk of breast cancer recurrence and mortality."
  },


  {
    "prompt": "What is the purpose of breast cancer staging?",
    "completion": "Breast cancer staging groups patients into risk categories that define prognosis and guide treatment recommendations for patients with similar prognosis."
  },
  {
    "prompt": "What are the two main types of breast cancer staging?",
    "completion": "Breast cancer staging is determined clinically based on physical examination and imaging before treatment, and histologically based on pathologic examination of the tumor and lymph nodes after surgery."
  },
  {
    "prompt": "What system is most widely used for breast cancer staging?",
    "completion": "The TNM classification system by the American Joint Committee on Cancer is the most widely used system for breast cancer staging."
  },
  {
    "prompt": "What does the 'T' in the TNM system represent in breast cancer staging?",
    "completion": "The 'T' represents the size and extent of the primary tumor, ranging from Tis (carcinoma in situ) to T4 (tumor with chest wall or skin involvement)."
  },
  {
    "prompt": "What are the size criteria for T1 tumors and its subcategories?",
    "completion": "T1 tumors are less than 2 cm, subdivided as T1a (0.1 to 0.5 cm), T1b (0.5 to 1.0 cm), and T1c (1.0 to 2.0 cm)."
  },
  {
    "prompt": "How is the regional lymph node involvement classified in breast cancer staging?",
    "completion": "Regional lymph nodes are classified as N1 (mobile ipsilateral axillary nodes), N2 (fixed/matted ipsilateral axillary nodes), and N3 with subcategories N3a (infraclavicular nodes), N3b (mammary nodes), and N3c (supraclavicular nodes)."
  },
  {
    "prompt": "What does M1 indicate in breast cancer staging?",
    "completion": "M1 indicates the presence of distant metastases."
  },
  {
    "prompt": "What breast cancer stages correspond to early invasive cancer?",
    "completion": "Stages I, IIa, and IIb are considered early invasive breast cancer."
  },
  {
    "prompt": "Which stages of breast cancer are classified as locally advanced disease?",
    "completion": "Stages IIIa, IIIb, and IIIc primarily involve locally advanced breast cancer."
  },
  {
    "prompt": "What defines Stage 0 breast cancer?",
    "completion": "Stage 0 comprises ductal carcinoma in situ (DCIS) and noninvasive breast cancer."
  },
  {
    "prompt": "What is the 5-year survival rate for Stage 0 and Stage I breast cancer?",
    "completion": "Both Stage 0 and Stage I breast cancer have a 100% 5-year survival rate."
  },
  {
    "prompt": "How does the 5-year survival rate change with Stage II and Stage III breast cancer?",
    "completion": "The 5-year survival rate is approximately 93% for Stage II and 72% for Stage III breast cancer."
  },
  {
    "prompt": "What is the prognosis for Stage IV metastatic breast cancer?",
    "completion": "Stage IV metastatic breast cancer has a poor prognosis, with only about 22% of patients surviving 5 years after diagnosis."
  },


  {
    "prompt": "What are some common surgical complications of breast cancer treatment?",
    "completion": "Surgical complications include infection, pain, bleeding, cosmetic issues, permanent scarring, and alteration or loss of sensation in the chest area and reconstructed breasts."
  },
  {
    "prompt": "What are typical chemotherapy-related complications in breast cancer patients?",
    "completion": "Common chemotherapy complications include nausea and vomiting, diarrhea, hair loss, memory loss ('chemo brain'), vaginal dryness, menopausal symptoms and fertility issues, and neuropathy."
  },
  {
    "prompt": "What side effects are associated with hormonal therapy in breast cancer treatment?",
    "completion": "Hormonal therapy side effects include hot flashes, vaginal discharge or dryness, fatigue, nausea, and impotence in males with breast cancer."
  },
  {
    "prompt": "What complications can arise from radiation therapy in breast cancer patients?",
    "completion": "Radiation therapy complications include pain and skin changes, fatigue, nausea, hair loss, chronic heart and lung issues, and neuropathy."
  },

  {
    "prompt": "What is the most common cause of lung cancer?",
    "completion": "Smoking is the most common cause of lung cancer, responsible for approximately 90% of cases."
  },
  {
    "prompt": "What percentage of lung cancer deaths are attributed to smoking?",
    "completion": "It is estimated that 90% of lung cancer cases are attributable to smoking."
  },
  {
    "prompt": "Which occupational exposure is a known risk factor for lung cancer?",
    "completion": "Asbestos exposure, especially occupational, is a well-established risk factor for lung cancer."
  },
  {
    "prompt": "Does passive smoking increase the risk of lung cancer?",
    "completion": "Yes, passive smoking increases the risk of lung cancer by 20% to 30%."
  },
  {
    "prompt": "How does idiopathic pulmonary fibrosis relate to lung cancer risk?",
    "completion": "Idiopathic pulmonary fibrosis increases the risk of lung cancer independent of smoking history."
  },
  {
    "prompt": "Which genetic mutations are commonly involved in non-small cell lung cancer?",
    "completion": "Common genetic mutations in non-small cell lung cancer include EGFR, KRAS, and p16."
  },
  {
    "prompt": "What are the leading genetic mutations associated with small cell lung cancer?",
    "completion": "The genetic mutations most often associated with small cell lung cancer are MYC, BCL2, and p53."
  },
  {
    "prompt": "What does the WHO 2021 classification of lung tumors emphasize?",
    "completion": "The 2021 WHO classification emphasizes histopathological subtyping and immunohistochemical staining in diagnosis and prognosis."
  },
  {
    "prompt": "Which subtype of lung cancer is associated with spread through air spaces and higher recurrence?",
    "completion": "Tumors that spread through air spaces are associated with a higher recurrence rate after limited resections."
  },
  {
    "prompt": "What percentage of global cancer deaths is caused by lung cancer according to 2020 data?",
    "completion": "Lung cancer was responsible for an estimated 1.8 million deaths globally in 2020."
  },
  {
    "prompt": "How does lung cancer mortality differ by sex in the United States?",
    "completion": "Lung cancer mortality is higher in men compared to women in the United States."
  },
  {
    "prompt": "Is there a racial disparity in lung cancer incidence?",
    "completion": "There is no racial difference in incidence, but the age-adjusted mortality rate is higher in African American males."
  },
  {
    "prompt": "What carcinogens besides smoking are linked to lung cancer?",
    "completion": "Besides smoking, asbestos, radon, chromium, nickel, arsenic, polycyclic aromatic hydrocarbons, and radiation are linked to lung cancer."
  },
  {
    "prompt": "What is the estimated annual incidence of lung cancer in the United States?",
    "completion": "The annual incidence is estimated at over 234,000 new lung cancer cases in the United States."
  },
  {
    "prompt": "What is the global incidence percentage of lung cancer among all cancers?",
    "completion": "Lung cancer accounts for approximately 12.4% of all cancer diagnoses worldwide."
  },
  {
    "prompt": "Which histopathological types are included in WHO’s classification of lung cancer?",
    "completion": "WHO classifies lung cancer into types like adenocarcinomas, squamous cell carcinomas, large cell carcinomas, sarcomatoid carcinomas, neuroendocrine tumors, and others."
  },
  {
    "prompt": "How has the trend in lung cancer changed over the 20th century?",
    "completion": "Lung cancer was rare at the beginning of the 20th century but rose dramatically due to increased smoking."
  },
  {
    "prompt": "Which subtype classification changes were made in the 2015 WHO system?",
    "completion": "Poorly differentiated carcinomas were reclassified based on immunohistochemical markers such as p40, TTF-1, and chromogranin."
  },
  {
    "prompt": "What role does radon play in lung cancer risk?",
    "completion": "Radon exposure, especially in uranium miners and residential settings, increases the risk of lung cancer and contributes to 2% of lung cancer deaths in Europe."
  },
  {
    "prompt": "Is lung cancer still considered a disease limited to developed countries?",
    "completion": "No, nearly 50% of new lung cancer cases are now diagnosed in underdeveloped countries."
  },


  {
    "prompt": "What are the two precursor glandular lesions of lung adenocarcinoma?",
    "completion": "The two precursor glandular lesions are atypical adenomatous hyperplasia (AAH) and adenocarcinoma in situ."
  },
  {
    "prompt": "What size defines atypical adenomatous hyperplasia (AAH)?",
    "completion": "AAH generally measures 5 mm or less."
  },
  {
    "prompt": "What is the characteristic growth pattern of adenocarcinoma in situ?",
    "completion": "Adenocarcinoma in situ shows a lepidic growth pattern, which is growth restricted along alveolar structures."
  },
  {
    "prompt": "What immunohistochemical markers are associated with adenocarcinoma?",
    "completion": "Thyroid transcription factor 1 (TTF-1) and napsin A are markers associated with adenocarcinoma."
  },
  {
    "prompt": "Which nonmucinous adenocarcinoma patterns are associated with poor prognosis?",
    "completion": "Solid, micropapillary, and cribriform patterns are associated with poor prognosis."
  },
  {
    "prompt": "What defines minimally invasive adenocarcinoma (MIA)?",
    "completion": "MIA is a solitary adenocarcinoma ≤3 cm in size with ≤5 mm invasion and a predominant lepidic pattern."
  },
  {
    "prompt": "What is invasive mucinous adenocarcinoma previously known as?",
    "completion": "It was previously referred to as mucinous bronchioloalveolar carcinoma."
  },
  {
    "prompt": "When should a lung tumor be classified as mixed adenocarcinoma?",
    "completion": "When the tumor contains more than 10% of both mucinous and nonmucinous growth patterns."
  },
  {
    "prompt": "What defines adenosquamous carcinoma?",
    "completion": "Adenosquamous carcinoma has more than 10% each of glandular and squamous components."
  },
  {
    "prompt": "Why is adjuvant chemotherapy recommended in Stage I adenosquamous carcinoma?",
    "completion": "Because adenosquamous carcinoma is highly aggressive and has a high risk of recurrence and brain metastasis."
  },
  {
    "prompt": "What are the key cytological features of squamous cell carcinoma?",
    "completion": "Keratin presence and/or intercellular desmosomes, or p40, p63, CK5/6 positivity on immunohistochemistry."
  },
  {
    "prompt": "What are the histological subtypes of squamous cell carcinoma?",
    "completion": "Subtypes include nonkeratinizing, keratinizing, and basaloid."
  },
  {
    "prompt": "What is a Pancoast tumor?",
    "completion": "A Pancoast tumor is a squamous cell carcinoma located in the superior sulcus of the lung."
  },
  {
    "prompt": "Which site is most commonly involved in recurrence of Pancoast tumors?",
    "completion": "The brain is the most common site of recurrence after surgery in Pancoast tumors."
  },
  {
    "prompt": "What defines large cell carcinoma histologically?",
    "completion": "Large cell carcinoma lacks features of glandular, squamous, or neuroendocrine differentiation and is diagnosed by exclusion."
  },
  {
    "prompt": "What are the cytologic features of large cell carcinoma?",
    "completion": "Large polygonal cells with prominent nucleoli and abundant cytoplasm without defining features."
  },
  {
    "prompt": "What are the subtypes of sarcomatoid carcinoma?",
    "completion": "Sarcomatoid carcinoma includes pleomorphic carcinoma, carcinosarcoma, and pulmonary blastoma."
  },
  {
    "prompt": "What are the histological features of small cell lung carcinoma?",
    "completion": "Small cells with scant cytoplasm, absent nucleoli, extensive necrosis, and round or angulated nuclei."
  },
  {
    "prompt": "Which immunohistochemical markers are used to identify small cell carcinoma?",
    "completion": "Chromogranin and synaptophysin are commonly used markers."
  },
  {
    "prompt": "Why is the older classification of small cell carcinoma into subtypes no longer used?",
    "completion": "Because studies showed that the classification had limited clinical significance or prognostic value."
  },


  {
    "prompt": "What percentage of patients with lung cancer present with a cough?",
    "completion": "Cough is present in 50 to 75% of patients with lung cancer."
  },
  {
    "prompt": "What type of sputum is associated with mucinous adenocarcinoma?",
    "completion": "Mucinous adenocarcinoma is associated with the production of large volumes of thin, mucoid secretions."
  },
  {
    "prompt": "How common is hemoptysis among patients with lung cancer?",
    "completion": "Hemoptysis is reported in 15 to 30% of patients with lung cancer."
  },
  {
    "prompt": "What is the prevalence of dyspnea at the time of lung cancer diagnosis?",
    "completion": "Dyspnea is present in approximately 25 to 40% of patients at diagnosis."
  },
  {
    "prompt": "What are the clinical features of superior vena cava syndrome in small cell lung cancer?",
    "completion": "Superior vena cava syndrome presents with dilated neck veins, facial and upper limb edema, plethoric appearance, and mediastinal widening on chest radiograph."
  },
  {
    "prompt": "What symptoms are seen in Pancoast syndrome?",
    "completion": "Pancoast syndrome includes shoulder pain, Horner syndrome, and atrophy of hand muscles due to bony destruction."
  },
  {
    "prompt": "How often do malignant pleural effusions occur in lung cancer patients?",
    "completion": "Malignant pleural effusions occur in approximately 10 to 15% of lung cancer patients during their illness."
  },
  {
    "prompt": "What is the significance of an ipsilateral malignant pleural effusion in lung cancer?",
    "completion": "Ipsilateral malignant pleural effusion in bronchogenic carcinoma is considered unresectable."
  },
  {
    "prompt": "What are possible causes of benign pleural effusions in lung cancer?",
    "completion": "Benign pleural effusions may result from lymphatic obstruction, post-obstructive pneumonitis, or atelectasis."
  },
  {
    "prompt": "What is the sensitivity of medical pleuroscopy for detecting malignant pleural disease?",
    "completion": "Medical pleuroscopy has a sensitivity greater than 90% for detecting malignancy in pleural space."
  },
  {
    "prompt": "What symptoms suggest bone metastasis in lung cancer patients?",
    "completion": "Bone pain at the site of metastasis, elevated alkaline phosphatase, and hypercalcemia suggest bone metastasis."
  },
  {
    "prompt": "Which bones are most commonly involved in lung cancer metastasis?",
    "completion": "The vertebral bodies are the most common site of bone metastasis in lung cancer."
  },
  {
    "prompt": "What percentage of non-small cell lung cancer (NSCLC) patients have bone metastasis at presentation?",
    "completion": "Up to 20% of NSCLC patients present with bone metastasis."
  },
  {
    "prompt": "What percentage of small cell lung cancer (SCLC) patients have bone metastasis at diagnosis?",
    "completion": "Bone metastases are seen in 30 to 40% of SCLC patients at diagnosis."
  },
  {
    "prompt": "Are adrenal metastases in lung cancer typically symptomatic?",
    "completion": "Adrenal metastases are usually asymptomatic and are often found incidentally during staging."
  },
  {
    "prompt": "How are adrenal lesions in lung cancer evaluated for malignancy?",
    "completion": "Positron emission tomography (PET) scans are used to differentiate benign from malignant adrenal lesions."
  },
  {
    "prompt": "What percentage of small cell lung cancer patients have brain metastases at diagnosis?",
    "completion": "Brain metastases are present in 20 to 30% of SCLC patients at diagnosis."
  },
  {
    "prompt": "Which metastatic site in lung cancer is often only symptomatic in advanced disease?",
    "completion": "Liver metastasis is usually asymptomatic and presents only in advanced disease."
  },
  {
    "prompt": "What clinical signs might suggest brain metastasis from lung cancer?",
    "completion": "Stroke-like symptoms may suggest brain metastasis from lung cancer."
  },
  {
    "prompt": "What non-specific symptom might indicate post-obstructive pneumonia in lung cancer?",
    "completion": "A persistent cough, especially in the presence of exophytic bronchial masses, may indicate post-obstructive pneumonia."
  },


  {
    "prompt": "What paraneoplastic syndrome causes hypercalcemia in lung cancer?",
    "completion": "Hypercalcemia in lung cancer can result from secretion of parathyroid hormone-related protein or from extensive bony metastases."
  },
  {
    "prompt": "Which symptoms indicate hypercalcemia in lung cancer patients?",
    "completion": "Symptoms of hypercalcemia include anorexia, nausea, constipation, and lethargy."
  },
  {
    "prompt": "Which type of lung cancer is most commonly associated with SIADH?",
    "completion": "SIADH is most commonly associated with small cell lung cancer (SCLC)."
  },
  {
    "prompt": "What neurologic paraneoplastic syndromes are associated with SCLC?",
    "completion": "Neurologic paraneoplastic syndromes include Lambert-Eaton myasthenic syndrome, encephalomyelitis, limbic encephalitis, cerebellar ataxia, sensory neuropathy, and autonomic neuropathy."
  },
  {
    "prompt": "What causes Cushing syndrome in lung cancer patients?",
    "completion": "Cushing syndrome may result from ectopic ACTH production, especially in SCLC, large cell neuroendocrine carcinoma, and carcinoid tumors."
  },
  {
    "prompt": "What are extrapulmonary manifestations of lung cancer besides paraneoplastic syndromes?",
    "completion": "Extrapulmonary manifestations include hypertrophic pulmonary osteoarthropathy, dermatomyositis, and polymyositis."
  },
  {
    "prompt": "What percentage of lung cancers are non-small cell lung cancer (NSCLC)?",
    "completion": "Non-small cell lung cancer accounts for approximately 85% of all lung cancer cases."
  },
  {
    "prompt": "What is the goal of initial lung cancer evaluation according to ACCP?",
    "completion": "The goal is timely diagnosis and accurate staging, ideally within six weeks if the patient has tolerable symptoms and no complications."
  },
  {
    "prompt": "What are the five key goals of initial lung cancer evaluation?",
    "completion": "The goals include determining clinical stage, identifying the optimal biopsy site and method, histologic subtype, co-morbidities including paraneoplastic syndromes, and patient preferences."
  },
  {
    "prompt": "What imaging test is recommended first for suspected lung cancer?",
    "completion": "Contrast-enhanced CT of the chest extended to the upper abdomen up to the adrenal glands is recommended first."
  },
  {
    "prompt": "When is PET or PET-CT imaging recommended in lung cancer?",
    "completion": "PET or PET-CT is recommended when CT shows advanced disease or symptoms/focal findings suggest metastasis."
  },
  {
    "prompt": "What is the sensitivity and specificity of CT scans for lung cancer staging?",
    "completion": "CT has a sensitivity of 55% and specificity of 81% for identifying malignant lymph nodes."
  },
  {
    "prompt": "How does the ACCP define a suspicious lymph node on CT scan?",
    "completion": "Lymph nodes ≥1 cm in short axis are considered suspicious for malignancy."
  },
  {
    "prompt": "What does CT scan help identify in lung cancer evaluation?",
    "completion": "CT helps identify tumor size, anatomical location, atelectasis, post-obstructive pneumonitis, metastatic disease, and coexisting lung disease."
  },
  {
    "prompt": "What defines Group A in the ACCP lung cancer radiologic staging?",
    "completion": "Group A includes patients with bulky tumors invading mediastinum where lymph nodes cannot be separated from the tumor, and no nodal sampling is needed."
  },
  {
    "prompt": "What defines Group B in the ACCP lung cancer radiologic staging?",
    "completion": "Group B includes patients with discrete lymph nodes >1 cm, requiring pathologic confirmation before curative therapy."
  },
  {
    "prompt": "What defines Group C in the ACCP lung cancer radiologic staging?",
    "completion": "Group C includes patients with central tumors and high risk of N2/N3 disease, requiring nodal sampling even if CT/PET is negative."
  },
  {
    "prompt": "What defines Group D in the ACCP lung cancer radiologic staging?",
    "completion": "Group D includes patients with low risk of N2/N3 disease or metastatic disease, where invasive testing is usually not required unless N1 is suspected."
  },
  {
    "prompt": "What is the main advantage of PET over CT in lung cancer staging?",
    "completion": "PET provides better metabolic assessment and reduces futile surgeries by detecting distant metastases."
  },
  {
    "prompt": "What are limitations of PET scan in lung cancer?",
    "completion": "PET scan can produce false positives in infections/inflammation and false negatives in carcinoid tumors or small low-metabolic lesions."
  },
  {
    "prompt": "Can a positive PET scan replace lymph node sampling in lung cancer?",
    "completion": "No, except in Group A disease, positive PET scan still requires nodal sampling to confirm staging."
  },


  {
    "prompt": "What is the main function of PET scanning in lung cancer?",
    "completion": "PET scanning assesses the metabolic activity of the primary tumor, mediastinal involvement, and distant metastases."
  },
  {
    "prompt": "What is a key advantage of integrated PET/CT scanners?",
    "completion": "Integrated PET/CT scanners eliminate anatomical uncertainty by combining metabolic and anatomic imaging."
  },
  {
    "prompt": "How has PET scanning reduced unnecessary surgeries in lung cancer?",
    "completion": "PET scanning reduces futile thoracotomies by accurately identifying distant metastases and ruling out surgical candidates."
  },
  {
    "prompt": "In what post-treatment setting is PET scan helpful for lung cancer patients?",
    "completion": "PET scan helps differentiate tumor recurrence from metabolic changes following radiation therapy."
  },
  {
    "prompt": "What conditions may lead to a false positive PET scan?",
    "completion": "False positives may occur due to infection, inflammation, or recent lymph node sampling, all of which increase glycolysis."
  },
  {
    "prompt": "What factors can cause a false negative PET scan?",
    "completion": "False negatives can occur with carcinoid tumors, some adenocarcinomas, low-metabolic lesions, or poor blood flow."
  },
  {
    "prompt": "What are the sensitivity and specificity of PET scan in lung cancer staging?",
    "completion": "PET scan has a sensitivity of 80% and specificity of 88% for lung cancer staging."
  },
  {
    "prompt": "Is PET scanning alone sufficient to stage lung cancer?",
    "completion": "No, PET scan alone is not sufficient; lymph node sampling is still required for accurate staging except in Group A cases."
  },
  {
    "prompt": "What is the ACCP’s stance on PET scans replacing nodal sampling?",
    "completion": "The ACCP recommends that PET scan does not replace lymph node sampling, except in Group A patients with bulky mediastinal disease."
  },
  {
    "prompt": "Why is PET scan preferred over CT in identifying metastasis?",
    "completion": "PET scan is preferred because it provides functional imaging that reveals metabolic activity, improving detection of occult metastases."
  },


  {
    "prompt": "What is the primary purpose of invasive staging in lung cancer?",
    "completion": "Invasive staging is used to obtain tissue confirmation of malignancy, confirm staging, and determine histological subtype."
  },
  {
    "prompt": "What procedures are used for invasive staging in lung cancer?",
    "completion": "Invasive staging techniques include endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA), endoscopic TBNA, mediastinoscopy, thoracoscopy, and video-assisted thoracoscopy (VATS)."
  },
  {
    "prompt": "What is CP-EBUS in the context of lung cancer staging?",
    "completion": "CP-EBUS stands for convex probe endobronchial ultrasound-guided transbronchial needle aspiration, used to biopsy mediastinal and hilar lymph nodes."
  },
  {
    "prompt": "What does RP-EBUS refer to in invasive lung cancer diagnosis?",
    "completion": "RP-EBUS refers to radial probe endobronchial ultrasound, used for peripheral pulmonary lesions."
  },
  {
    "prompt": "When is a CT-guided transthoracic biopsy preferred?",
    "completion": "CT-guided transthoracic biopsy is preferred for peripheral lung lesions, especially when the risk of pneumothorax is low."
  },
  {
    "prompt": "What older surgical procedure might be used in rare cases for staging lung cancer?",
    "completion": "The Chamberlain procedure, a surgical mediastinal lymph node biopsy, may be used in select cases."
  },
  {
    "prompt": "What is navigation bronchoscopy used for in lung cancer evaluation?",
    "completion": "Navigation bronchoscopy is used to access and biopsy peripheral or difficult-to-reach lung nodules using 3D guidance systems."
  },
  {
    "prompt": "Which minimally invasive procedure helps assess mediastinal lymph nodes?",
    "completion": "Endobronchial ultrasound-guided TBNA (EBUS-TBNA) is commonly used to assess mediastinal lymph nodes."
  },
  {
    "prompt": "What role does video-assisted thoracoscopy (VATS) play in lung cancer staging?",
    "completion": "VATS allows for direct visualization and biopsy of pleural and lung tissue, aiding in staging and diagnosis."
  },
  {
    "prompt": "Why is mediastinoscopy used in lung cancer staging?",
    "completion": "Mediastinoscopy provides direct access to mediastinal lymph nodes for biopsy to confirm nodal involvement."
  },



  {
    "prompt": "What does CP-EBUS stand for in bronchoscopy?",
    "completion": "CP-EBUS stands for convex probe-endobronchial ultrasound bronchoscopy."
  },
  {
    "prompt": "What is the frequency of the ultrasound probe used in CP-EBUS?",
    "completion": "CP-EBUS uses a 7.5 MHz convex ultrasound probe."
  },
  {
    "prompt": "What is the primary purpose of CP-EBUS?",
    "completion": "CP-EBUS is primarily used to sample mediastinal and hilar lymph nodes in real time."
  },
  {
    "prompt": "Which lymph node stations can CP-EBUS access?",
    "completion": "CP-EBUS can access upper and lower paratracheal nodes and stations 10, 11, and 12."
  },
  {
    "prompt": "Which lymph node stations cannot be accessed by CP-EBUS?",
    "completion": "CP-EBUS cannot access stations 3, 5, and 6."
  },
  {
    "prompt": "Why is Doppler imaging used during CP-EBUS?",
    "completion": "Doppler imaging is used to identify blood vessels and avoid vascular injury during biopsy."
  },
  {
    "prompt": "What is a key application of CP-EBUS after induction chemotherapy?",
    "completion": "CP-EBUS is used to confirm complete remission before surgery after induction chemotherapy."
  },
  {
    "prompt": "How does RP-EBUS differ from CP-EBUS?",
    "completion": "RP-EBUS uses a higher frequency probe (20–30 MHz), offers a 360-degree lung view, and targets smaller peripheral lesions but does not allow real-time biopsy."
  },
  {
    "prompt": "What is the main advantage of RP-EBUS?",
    "completion": "RP-EBUS can reach smaller and more peripheral lung lesions and provides a 360-degree view of the parenchyma."
  },
  {
    "prompt": "What is a key limitation of RP-EBUS?",
    "completion": "Real-time biopsy cannot be performed with RP-EBUS."
  },
  {
    "prompt": "What is the concept behind navigation bronchoscopy?",
    "completion": "Navigation bronchoscopy creates a 3D map of airways using CT or electromagnetic fields to guide the bronchoscopist to the target lesion."
  },
  {
    "prompt": "What imaging is used to plan a pathway in navigation bronchoscopy?",
    "completion": "CT scans or electromagnetic field mapping is used to create a navigational pathway."
  },
  {
    "prompt": "What is endoscopic TBNA also known as?",
    "completion": "Endoscopic TBNA is also referred to as endoscopic ultrasound (EUS)-guided TBNA."
  },
  {
    "prompt": "Which lymph node stations are accessible via endoscopic-TBNA (EUS)?",
    "completion": "EUS can sample lymph node stations 2, 4, 7, 8, and 9."
  },
  {
    "prompt": "Which lymph node stations are not accessible via EBUS but accessible via EUS?",
    "completion": "Stations 8 and 9 can be accessed by EUS but not by EBUS."
  },
  {
    "prompt": "What is the sensitivity and specificity of endoscopic-TBNA?",
    "completion": "Endoscopic-TBNA has a sensitivity of 89% and a specificity of 100%."
  },
  {
    "prompt": "Why is a combined EBUS and EUS approach recommended for lung cancer staging?",
    "completion": "Combining EBUS and EUS increases lymph node coverage and offers a comprehensive, minimally invasive staging strategy."
  },


  {
    "prompt": "What is the primary clinical indication for mediastinoscopy in lung cancer staging?",
    "completion": "Mediastinoscopy is used when needle-based techniques are negative but clinical suspicion of malignancy remains due to lymph node size or PET uptake."
  },
  {
    "prompt": "Which lymph nodes are typically accessed during standard mediastinoscopy?",
    "completion": "Standard mediastinoscopy typically samples paratracheal lymph nodes."
  },
  {
    "prompt": "What is the anterior mediastinoscopy (Chamberlain procedure) used for?",
    "completion": "The Chamberlain procedure is used to access subaortic and para-aortic lymph nodes, corresponding to stations 5 and 6."
  },
  {
    "prompt": "What is the sensitivity and specificity of mediastinoscopy?",
    "completion": "Mediastinoscopy has a sensitivity of 78% and a specificity of 100%."
  },
  {
    "prompt": "What is the mortality risk associated with mediastinoscopy?",
    "completion": "The mortality risk of mediastinoscopy is approximately 0.08%."
  },
  {
    "prompt": "Why is general anesthesia required for mediastinoscopy?",
    "completion": "Mediastinoscopy is a surgical procedure requiring airway control and precise dissection near vital structures, necessitating general anesthesia."
  },
  {
    "prompt": "What is thoracoscopy traditionally, and what has replaced it?",
    "completion": "Thoracoscopy traditionally involved opening the chest cavity, but it has been replaced by minimally invasive video-assisted thoracoscopic surgery (VATS)."
  },
  {
    "prompt": "What procedures can be performed using VATS in lung cancer management?",
    "completion": "VATS allows mediastinal lymph node biopsy, full dissection during lung resection, and treatment of pleural, pulmonary, and chest wall conditions."
  },
  {
    "prompt": "What is RATS in thoracic surgery?",
    "completion": "RATS stands for robotic-assisted thoracoscopy, a newer version of VATS using robotic instruments for improved precision."
  },
  {
    "prompt": "Are there trials comparing VATS and RATS for mediastinal lymph node sampling?",
    "completion": "No, there are currently no trials directly comparing VATS and RATS for mediastinal lymph node biopsy."
  },


  {
    "prompt": "What is the treatment of choice for Stage I non-small cell lung cancer (NSCLC)?",
    "completion": "Surgery is the mainstay of treatment for Stage I NSCLC, typically via lobectomy or pneumonectomy with mediastinal lymph node sampling."
  },
  {
    "prompt": "What is the 5-year survival rate for Stage IA NSCLC?",
    "completion": "The 5-year survival rate for Stage IA NSCLC is approximately 78%."
  },
  {
    "prompt": "What is the 5-year survival rate for Stage IB NSCLC?",
    "completion": "The 5-year survival rate for Stage IB NSCLC is approximately 53%."
  },
  {
    "prompt": "What surgical options exist for patients who cannot tolerate lobectomy or pneumonectomy?",
    "completion": "Patients with limited pulmonary reserve may undergo wedge resection or segmentectomy as more conservative options."
  },
  {
    "prompt": "What is a disadvantage of sublobar resection in Stage I NSCLC?",
    "completion": "Sublobar resections like wedge or segmentectomy have a higher local recurrence rate compared to lobectomy."
  },
  {
    "prompt": "Does conservative surgery affect survival in Stage I NSCLC?",
    "completion": "No, despite a higher local recurrence rate, overall survival is similar between conservative and standard surgeries in Stage I NSCLC."
  },
  {
    "prompt": "Is postoperative radiation therapy beneficial in Stage I NSCLC?",
    "completion": "No, local postoperative radiation therapy has not shown a survival benefit in Stage I NSCLC."
  },
  {
    "prompt": "Is adjuvant chemotherapy recommended for Stage I NSCLC?",
    "completion": "Adjuvant chemotherapy has not been shown to improve outcomes in Stage I NSCLC."
  },


  {
    "prompt": "What is the preferred treatment for Stage II NSCLC?",
    "completion": "The preferred treatment for Stage II NSCLC is surgery followed by adjuvant chemotherapy."
  },
  {
    "prompt": "What are the 5-year survival rates for Stage IIA and IIB NSCLC?",
    "completion": "The 5-year survival rate is 46% for Stage IIA and 36% for Stage IIB NSCLC."
  },
  {
    "prompt": "What surgical approach is recommended for NSCLC invading the chest wall?",
    "completion": "En-bloc resection of the chest wall is recommended when the tumor invades the chest wall."
  },
  {
    "prompt": "What is a Pancoast tumor?",
    "completion": "A Pancoast tumor is a lung cancer arising from the superior sulcus, typically diagnosed at Stage IIB or IIIA."
  },
  {
    "prompt": "What is the standard treatment approach for Pancoast tumors?",
    "completion": "The standard treatment for Pancoast tumors is neoadjuvant chemotherapy with cisplatin and etoposide along with concurrent radiotherapy, followed by surgical resection."
  },
  {
    "prompt": "Which chemotherapy drugs are commonly used in neoadjuvant therapy for Pancoast tumors?",
    "completion": "Cisplatin and etoposide are commonly used in neoadjuvant chemotherapy for Pancoast tumors."
  },
  {
    "prompt": "What is the survival range for patients with resected Pancoast tumors?",
    "completion": "The overall survival for patients with Pancoast tumors ranges from 44% to 54%, depending on the presence or absence of microscopic disease in the resected specimen."
  },



  {
    "prompt": "What is the preferred treatment for Stage IIIA NSCLC with N1 lymph node involvement?",
    "completion": "Surgery with curative intent is the treatment of choice for Stage IIIA NSCLC with N1 lymph node involvement."
  },
  {
    "prompt": "What is the current consensus for Stage IIIA NSCLC patients found to have N2 lymph node involvement at resection?",
    "completion": "The consensus is to perform surgery followed by adjuvant chemotherapy for Stage IIIA NSCLC patients with N2 lymph node involvement."
  },
  {
    "prompt": "What treatment is recommended for Stage IIIA NSCLC patients with N2 or N3 lymph node disease and good performance status?",
    "completion": "Concurrent chemoradiotherapy offers the best outcome for Stage IIIA NSCLC patients with N2/N3 lymph node disease who have good performance status and no weight loss."
  },
  {
    "prompt": "What are common side effects and tolerance concerns associated with concurrent chemoradiotherapy in Stage III NSCLC?",
    "completion": "Concurrent chemoradiotherapy is not well tolerated by all patients and can cause severe esophagitis."
  },
  {
    "prompt": "What is the five-year survival rate for Stage III NSCLC after concurrent chemo-radiotherapy?",
    "completion": "The five-year survival rate for Stage III NSCLC after concurrent chemo-radiotherapy is approximately 20%."
  },
  {
    "prompt": "How are T4 NSCLC tumors usually treated?",
    "completion": "T4 tumors are usually treated exclusively with chemoradiation."
  },
  {
    "prompt": "When might surgery be an option for T4 NSCLC tumors?",
    "completion": "Surgery may be considered in T4 N0-1 tumors with carinal involvement."
  },
  {
    "prompt": "What is the operative mortality and approximate survival rate after carinal resection for T4 NSCLC?",
    "completion": "Operative mortality after carinal resection is 10% to 15%, with an approximate survival rate of 20%."
  },
  {
    "prompt": "What is the prognosis for T4 tumors with ipsilateral nonprimary lobe nodules and no mediastinal involvement treated with surgery alone?",
    "completion": "Surgery alone in T4 tumors with ipsilateral nonprimary lobe nodules and no mediastinal involvement offers a five-year survival rate of about 20%."
  },
  {
    "prompt": "How are Stage IIIB NSCLC tumors generally treated?",
    "completion": "Stage IIIB NSCLC tumors are treated similarly to unresectable Stage IIIA cancers, primarily with concurrent chemoradiotherapy."
  },
  {
    "prompt": "Is surgery an option for Stage IIIB NSCLC after induction chemo-radiotherapy?",
    "completion": "In select Stage IIIB NSCLC patients, surgery may be considered after induction chemo-radiotherapy."
  },
  {
    "prompt": "Why is the exact survival rate of Stage IIIB NSCLC unclear?",
    "completion": "Survival data for Stage IIIB NSCLC is unclear because trials have included both inoperable Stage IIIA and Stage IIIB patients together."
  },


  {
    "prompt": "Is Stage IV NSCLC considered curable?",
    "completion": "No, Stage IV NSCLC is considered incurable; treatment aims to improve survival and relieve symptoms."
  },
  {
    "prompt": "What percentage of Stage IV NSCLC patients typically respond to chemotherapy?",
    "completion": "Only about 10% to 30% of Stage IV NSCLC patients respond to chemotherapy."
  },
  {
    "prompt": "What is the five-year survival rate for patients with Stage IV NSCLC?",
    "completion": "Only 1% to 3% of patients with Stage IV NSCLC survive five years after diagnosis."
  },
  {
    "prompt": "What chemotherapy regimens are offered to Stage IV NSCLC patients?",
    "completion": "Single or double drug-based chemotherapy is offered to Stage IV NSCLC patients with good functional performance status."
  },
  {
    "prompt": "What is the survival benefit of chemotherapy in Stage IV NSCLC?",
    "completion": "Chemotherapy offers a small survival benefit in Stage IV NSCLC."
  },
  {
    "prompt": "Which Stage IV NSCLC patients might benefit from bevacizumab therapy?",
    "completion": "Highly selected patients with non-squamous NSCLC without brain metastasis or hemoptysis may benefit from the addition of bevacizumab."
  },
  {
    "prompt": "What is the mechanism of action of bevacizumab in NSCLC treatment?",
    "completion": "Bevacizumab is a vascular endothelial growth factor (VEGF) inhibitor that targets tumor angiogenesis."
  },


  {
    "prompt": "What are 'driver mutations' in NSCLC?",
    "completion": "Driver mutations are specific genetic alterations that encode critical proteins responsible for cell growth and replication in NSCLC."
  },
  {
    "prompt": "Why is it important to test for driver mutations in advanced NSCLC?",
    "completion": "Testing for driver mutations in advanced NSCLC is important because targeted inhibitors are available for these mutations, which can improve patient survival."
  },
  {
    "prompt": "Which mutation is targeted by the tyrosine kinase inhibitors erlotinib, gefitinib, and afatinib?",
    "completion": "The epidermal growth factor receptor (EGFR) mutation is targeted by the tyrosine kinase inhibitors erlotinib, gefitinib, and afatinib."
  },
  {
    "prompt": "Name the inhibitors used for ALK mutation in NSCLC.",
    "completion": "Crizotinib, ceritinib, and alectinib are specific inhibitors used to target the ALK mutation in NSCLC."
  },
  {
    "prompt": "What is ROS-1 mutation and how is it treated in NSCLC?",
    "completion": "ROS-1 is a mutation structurally similar to ALK and is treated with crizotinib, which is FDA approved for cancers expressing ROS-1 mutation."
  },


  {
    "prompt": "What is the basic mechanism of action of immunotherapy in NSCLC?",
    "completion": "Immunotherapy boosts the immune system, helping it recognize cancer cells as foreign and increases their responsiveness against tumors."
  },
  {
    "prompt": "How do malignant cells evade the immune system via checkpoints?",
    "completion": "Malignant cells co-opt immune checkpoints such as PD-1, creating tolerance in the immune system and rendering it less effective against tumor cells."
  },
  {
    "prompt": "What role does PD-1 play in immune regulation?",
    "completion": "PD-1 down-regulates T-cells and promotes self-tolerance, but its interaction with PD-L1 or PD-L2 inactivates activated T-cells, decreasing immune response to tumors."
  },
  {
    "prompt": "Which immune checkpoints are currently targeted by approved antibodies in NSCLC?",
    "completion": "Antibodies targeting PD-1 and its ligand PD-L1 are currently approved for immunotherapy in NSCLC."
  },
  {
    "prompt": "What is nivolumab and its approved use in NSCLC?",
    "completion": "Nivolumab is an IgG4 monoclonal antibody against PD-1 approved for squamous and non-squamous NSCLC that has progressed after platinum-based chemotherapy, usable regardless of PD-L1 expression levels."
  },
  {
    "prompt": "How is pembrolizumab used in NSCLC treatment?",
    "completion": "Pembrolizumab is an IgG4 monoclonal antibody against PD-1 approved for metastatic NSCLC with PD-L1 expression >50%, no EGFR or ALK mutations, and is combined with chemotherapy for non-squamous NSCLC with <50% PD-L1 expression."
  },
  {
    "prompt": "Describe atezolizumab’s mechanism and indications in NSCLC.",
    "completion": "Atezolizumab is an IgG1 antibody against PD-L1 approved for metastatic, progressive NSCLC during or after platinum-based chemotherapy, including patients with EGFR and ALK mutations who failed targeted therapy."
  },
  {
    "prompt": "Is bevacizumab considered an immunotherapy agent in NSCLC?",
    "completion": "No, bevacizumab is an anti-angiogenesis antibody targeting VEGF-A, primarily used with chemotherapy for non-squamous NSCLC and is contraindicated in squamous cell NSCLC."
  },
  {
    "prompt": "Why is bevacizumab contraindicated in squamous cell NSCLC?",
    "completion": "Bevacizumab is contraindicated in squamous cell NSCLC due to the risk of severe and often fatal hemoptysis."
  },


  {
    "prompt": "How does small cell lung cancer (SCLC) typically respond to chemotherapy?",
    "completion": "SCLC is highly sensitive to chemotherapy but has a very high recurrence rate."
  },
  {
    "prompt": "What is the treatment for Stage I limited-stage SCLC presenting as a peripheral nodule without lymphadenopathy?",
    "completion": "The treatment is lobectomy followed by adjuvant chemotherapy."
  },
  {
    "prompt": "What must be done before confirming limited-stage SCLC without lymphadenopathy?",
    "completion": "PET-CT followed by lymph node sampling via EBUS bronchoscopy or mediastinoscopy should be performed to rule out nodal involvement, even if PET-CT is negative."
  },
  {
    "prompt": "What is the standard treatment for LS-SCLC with mediastinal or hilar lymph node involvement?",
    "completion": "The standard treatment is 4 to 6 cycles of chemotherapy followed by radiation therapy."
  },
  {
    "prompt": "Why is radiation therapy used in limited-stage SCLC with nodal involvement?",
    "completion": "Radiation therapy is used because up to 80% of SCLC recurs locally without it."
  },
  {
    "prompt": "What are the treatment options for chemotherapy and radiation in LS-SCLC?",
    "completion": "Options include concurrent chemo-radiotherapy, alternating therapy, and sequential therapy. Concurrent/alternate approaches offer better outcomes but are more toxic, while sequential therapy is better tolerated."
  },
  {
    "prompt": "What additional therapy is used in patients with LS-SCLC who achieve remission?",
    "completion": "Prophylactic whole-brain radiation is used to reduce symptomatic brain metastases and improve survival."
  },


  {
    "prompt": "What defines extensive-stage small cell lung cancer (ES-SCLC)?",
    "completion": "ES-SCLC includes distant metastasis, malignant pleural or pericardial effusions, and contralateral hilar or supraclavicular lymph node involvement."
  },
  {
    "prompt": "What is the standard treatment for ES-SCLC?",
    "completion": "Platinum-based chemotherapy is the standard treatment for ES-SCLC."
  },
  {
    "prompt": "What percentage of ES-SCLC patients show remission after chemotherapy?",
    "completion": "Approximately 50% to 60% of ES-SCLC patients show remission after platinum-based chemotherapy."
  },
  {
    "prompt": "What additional therapies are recommended after remission in ES-SCLC?",
    "completion": "Radiation therapy followed by prophylactic whole-brain irradiation is recommended after remission."
  },
  {
    "prompt": "What is the median survival of patients diagnosed with ES-SCLC?",
    "completion": "The median survival for ES-SCLC patients is approximately 8 to 13 months from diagnosis."
  },
  {
    "prompt": "What is the two-year survival rate for ES-SCLC patients?",
    "completion": "Only about 5% of ES-SCLC patients survive two years after diagnosis."
  },


  {
    "prompt": "What are some conditions that may mimic the presentation of lung cancer?",
    "completion": "Conditions that can mimic lung cancer include bacterial pneumonia, bronchitis, mycoplasmal pneumonia, pleural effusion, pneumothorax, tuberculosis, viral pneumonia, and fungal pneumonia."
  },
  {
    "prompt": "Which infectious diseases should be considered in the differential diagnosis of a lung mass?",
    "completion": "Infectious diseases to consider include bacterial pneumonia, tuberculosis, viral pneumonia, fungal pneumonia, and mycoplasmal pneumonia."
  },
  {
    "prompt": "What pulmonary conditions may cause symptoms similar to lung cancer such as cough and chest pain?",
    "completion": "Pulmonary conditions with similar symptoms include bronchitis, pneumothorax, and pleural effusion."
  },
  {
    "prompt": "Can tuberculosis be misdiagnosed as lung cancer?",
    "completion": "Yes, tuberculosis can mimic lung cancer clinically and radiologically and must be included in the differential diagnosis."
  },
  {
    "prompt": "Why is mycoplasmal pneumonia a potential differential diagnosis for lung cancer?",
    "completion": "Mycoplasmal pneumonia can cause chronic cough and infiltrates on imaging, which may resemble lung cancer."
  },


  {
    "prompt": "Why is staging crucial after a lung cancer diagnosis?",
    "completion": "Staging is essential because it guides treatment decisions, impacts prognosis and survival, and determines whether surgery or palliative care is appropriate."
  },
  {
    "prompt": "What is the standard system used for staging non-small cell lung cancer (NSCLC)?",
    "completion": "The Tumor, Node, Metastasis (TNM) classification system is the internationally accepted standard for staging NSCLC."
  },
  {
    "prompt": "Which edition of the TNM classification is currently in use for lung cancer staging?",
    "completion": "The 8th edition of the TNM classification is currently in use for lung cancer staging, effective in the U.S. since January 1, 2018."
  },
  {
    "prompt": "Which organization led the development of the 8th edition of TNM staging for lung cancer?",
    "completion": "The 8th edition was developed by the International Association for the Study of Lung Cancer (IASLC)."
  },
  {
    "prompt": "How many countries contributed data to the 8th edition TNM staging system for lung cancer?",
    "completion": "Data from 16 countries and approximately 95,000 patients were analyzed to develop the 8th edition TNM system."
  },
  {
    "prompt": "What does T0 mean in lung cancer staging?",
    "completion": "T0 means no evidence of a primary tumor."
  },
  {
    "prompt": "What is Tis in lung cancer staging?",
    "completion": "Tis represents carcinoma in situ, a non-invasive tumor confined to the epithelium."
  },
  {
    "prompt": "What are the subcategories of T1 tumors in lung cancer?",
    "completion": "T1 tumors are less than 3 cm and include: T1mi (minimally invasive), T1a (superficial), T1a (<1 cm), T1b (1–2 cm), and T1c (2–3 cm)."
  },
  {
    "prompt": "What tumor size defines a T2 lung tumor?",
    "completion": "T2 tumors are greater than 3 cm but less than 5 cm in diameter."
  },
  {
    "prompt": "Which anatomical features qualify a tumor as T2 even if the size is <5 cm?",
    "completion": "A tumor involving the main bronchus (not at the carina), visceral pleura, or causing atelectasis extending to the hilum is also considered T2."
  },
  {
    "prompt": "What defines a T3 tumor in lung cancer?",
    "completion": "T3 tumors are 5–7 cm or invade the chest wall, pericardium, phrenic nerve, or have separate tumor nodules in the same lobe."
  },
  {
    "prompt": "What size defines a T4 tumor in lung cancer?",
    "completion": "T4 tumors are greater than 7 cm."
  },
  {
    "prompt": "What anatomical invasions qualify a tumor as T4?",
    "completion": "T4 tumors invade the heart, great vessels, esophagus, trachea, carina, mediastinum, vertebral body, recurrent laryngeal nerve, or diaphragm."
  },
  {
    "prompt": "How did diaphragm involvement change from the 7th to the 8th TNM edition?",
    "completion": "In the 8th edition, diaphragm invasion is classified as T4, whereas it was previously T3 in the 7th edition."
  },
  {
    "prompt": "How are multiple tumor nodules classified in the TNM system?",
    "completion": "Separate tumor nodules in the same lobe are T3, in a different ipsilateral lobe are T4, and in the contralateral lung are M1a."
  },
  {
    "prompt": "Is the TNM system used for staging small cell lung cancer (SCLC)?",
    "completion": "Although SCLC can be staged using TNM, it is commonly classified into limited-stage and extensive-stage disease for practical treatment purposes."
  },


  {
    "prompt": "Why is lymph node staging critical before performing lung cancer surgery?",
    "completion": "Lymph node staging is critical to determine if curative surgery is feasible, as lung resection carries high morbidity and should be avoided in unresectable disease."
  },
  {
    "prompt": "Which lymph nodes are most relevant in differentiating lung cancer stages?",
    "completion": "Mediastinal or N2 lymph nodes are most critical in differentiating lung cancer stages and influencing treatment options."
  },
  {
    "prompt": "Who developed the first widely accepted thoracic lymph node map?",
    "completion": "The first widely accepted thoracic lymph node map was developed by Naruke in the 1960s."
  },
  {
    "prompt": "What were the two major lymph node classification systems in North America before standardization?",
    "completion": "The American Thoracic Society (ATS) map and the American Joint Committee on Cancer (AJCC) map were the two main classification systems."
  },
  {
    "prompt": "What was the Mountain-Dressler modification?",
    "completion": "The Mountain-Dressler modification (MD-ATS map) was a unification of the ATS and AJCC maps, widely adopted in North America in 1996."
  },
  {
    "prompt": "Which organization created the globally accepted lymph node map for lung cancer staging?",
    "completion": "The International Association for the Study of Lung Cancer (IASLC) developed the globally accepted lymph node map for lung cancer staging."
  },
  {
    "prompt": "How are thoracic lymph nodes broadly divided in lung cancer staging?",
    "completion": "Thoracic lymph nodes are divided into mediastinal (N2) and hilar (N1) groups."
  },
  {
    "prompt": "Which lymph node group has a greater impact on lung cancer staging and treatment decisions?",
    "completion": "Mediastinal (N2) lymph nodes have a greater impact on staging and treatment decisions than hilar (N1) nodes."
  },
  {
    "prompt": "What are the major groups of mediastinal lymph nodes per the IASLC map?",
    "completion": "Mediastinal lymph nodes are divided into supraclavicular nodes (station 1), superior mediastinal nodes (stations 2–4), aortic nodes (station 5), and inferior mediastinal nodes (station 7–9)."
  },
  {
    "prompt": "What is the classification of station 1 lymph nodes?",
    "completion": "Station 1 lymph nodes refer to supraclavicular nodes."
  },
  {
    "prompt": "Which stations are included in the superior mediastinal group of lymph nodes?",
    "completion": "Superior mediastinal lymph nodes include stations 2, 3, and 4."
  },
  {
    "prompt": "What does station 5 in the IASLC lymph node map represent?",
    "completion": "Station 5 represents aortic nodes, which include subaortic lymph nodes (aortopulmonary window)."
  },
  {
    "prompt": "What classification system is used globally today for thoracic lymph node staging in lung cancer?",
    "completion": "The IASLC lymph node map is the most widely used global standard for thoracic lymph node staging in lung cancer."
  },


  {
    "prompt": "What does station 1 in the IASLC lymph node map represent?",
    "completion": "Station 1 includes lower cervical, supraclavicular, and sternal notch lymph nodes."
  },
  {
    "prompt": "How is station 1 divided in the IASLC lymph node classification?",
    "completion": "Station 1 is divided into 1R and 1L, based on the imaginary midline of the trachea."
  },
  {
    "prompt": "What anatomical landmark separates 1R from 1L lymph nodes?",
    "completion": "The imaginary midline of the trachea separates 1R from 1L; below station 1, the left tracheal border is used."
  },
  {
    "prompt": "Which stations are part of the superior mediastinal lymph nodes in IASLC map?",
    "completion": "Stations 2, 3, and 4 are categorized under superior mediastinal lymph nodes."
  },
  {
    "prompt": "What does station 2R represent in the IASLC lymph node map?",
    "completion": "Station 2R represents right upper paratracheal lymph nodes, from the upper manubrium to the caudal margin of the innominate vein, extending to the left lateral border of the trachea."
  },
  {
    "prompt": "What does station 2L represent in the IASLC lymph node map?",
    "completion": "Station 2L represents left upper paratracheal lymph nodes, from the upper border of the manubrium to the top of the aortic arch, located left of the left lateral tracheal border."
  },
  {
    "prompt": "What does station 3A include in the IASLC lymph node map?",
    "completion": "Station 3A includes pre-vascular lymph nodes located anterior to great vessels but not adjacent to the trachea."
  },
  {
    "prompt": "What does station 3P include in the IASLC lymph node map?",
    "completion": "Station 3P includes pre-vertebral lymph nodes located behind the esophagus and not adjacent to the trachea."
  },
  {
    "prompt": "What does station 4R represent in the IASLC lymph node map?",
    "completion": "Station 4R represents right lower paratracheal lymph nodes from the caudal margin of the innominate vein to the lower border of the azygos vein, spanning the trachea."
  },
  {
    "prompt": "What does station 4L represent in the IASLC lymph node map?",
    "completion": "Station 4L represents left lower paratracheal lymph nodes from the upper margin of the aortic arch to the upper rim of the left pulmonary artery."
  },


  {
    "prompt": "What does station 5 in the IASLC lymph node map represent?",
    "completion": "Station 5 represents sub-aortic lymph nodes located lateral to the aorta and pulmonary trunk in the aortopulmonary (AP) window."
  },
  {
    "prompt": "What does station 6 in the IASLC lymph node map represent?",
    "completion": "Station 6 represents para-aortic lymph nodes lying anterior and lateral to the ascending aorta and the aortic arch."
  },
  {
    "prompt": "What does station 7 in the IASLC lymph node map represent?",
    "completion": "Station 7 includes sub-carinal lymph nodes extending from the carina to the lower border of the bronchus intermedius on the right and upper border of the lower lobe bronchus on the left."
  },
  {
    "prompt": "What does station 8 in the IASLC lymph node map represent?",
    "completion": "Station 8 includes para-esophageal lymph nodes located adjacent to the esophageal wall on both right and left sides, below the carina."
  },
  {
    "prompt": "What does station 9 in the IASLC lymph node map represent?",
    "completion": "Station 9 includes lymph nodes located within the pulmonary ligament, extending from the inferior pulmonary vein to the diaphragm."
  },



  {
    "prompt": "What does M0 indicate in lung cancer staging?",
    "completion": "M0 indicates no distant metastasis."
  },
  {
    "prompt": "What is the meaning of M1a in lung cancer staging?",
    "completion": "M1a indicates the presence of malignant pleural or pericardial effusion or malignant nodules within the thoracic cavity."
  },
  {
    "prompt": "What does M1b signify in lung cancer staging?",
    "completion": "M1b refers to a single extra-thoracic metastasis."
  },
  {
    "prompt": "What does M1c represent in lung cancer staging?",
    "completion": "M1c represents multiple extra-thoracic metastases."
  },
  {
    "prompt": "What is the TNM classification for occult lung cancer?",
    "completion": "Occult lung cancer is classified as TX N0 M0, meaning the primary tumor is not found, and there is no lymph node or distant metastasis."
  },
  {
    "prompt": "What is Stage 0 in lung cancer staging?",
    "completion": "Stage 0 is defined as Tis N0 M0, where the tumor is carcinoma in situ, with no lymph node or distant metastasis."
  },
  {
    "prompt": "Describe Stage IA1 lung cancer TNM classification.",
    "completion": "Stage IA1 includes T1mi or T1a tumors, with no lymph node (N0) or distant metastasis (M0)."
  },
  {
    "prompt": "What is Stage IA2 in lung cancer staging?",
    "completion": "Stage IA2 is defined by a T1b tumor with no lymph node involvement (N0) and no distant metastasis (M0)."
  },
  {
    "prompt": "Describe the TNM classification for Stage IA3 lung cancer.",
    "completion": "Stage IA3 includes T1c tumors with N0 and M0."
  },
  {
    "prompt": "What does Stage IB represent in lung cancer TNM staging?",
    "completion": "Stage IB is characterized by T2a tumors with no lymph node involvement (N0) and no distant metastasis (M0)."
  },
  {
    "prompt": "What TNM features define Stage IIA lung cancer?",
    "completion": "Stage IIA includes T2b tumors with N0 and M0."
  },
  {
    "prompt": "Describe the TNM classification for Stage IIB lung cancer.",
    "completion": "Stage IIB includes T1a, T1b, or T1c tumors with N1 and M0; T2a or T2b tumors with N1 and M0; and T3 tumors with N0 and M0."
  },
  {
    "prompt": "What defines Stage IIIA lung cancer in TNM terms?",
    "completion": "Stage IIIA consists of T1a, T2b, or T2c tumors with N2 and M0; T2a or T2b tumors with N2 and M0; T3 tumors with N1 and M0; and T4 tumors with N0 or N1 and M0."
  },
  {
    "prompt": "What is the TNM classification for Stage IIIB lung cancer?",
    "completion": "Stage IIIB includes T1a, T1b, or T1c tumors with N3 and M0; T2a or T2b tumors with N3 and M0; T3 tumors with N2 and M0; and T4 tumors with N2 and M0."
  },
  {
    "prompt": "Describe Stage IIIC lung cancer in TNM staging.",
    "completion": "Stage IIIC is characterized by T3 tumors with N3 and M0, and T4 tumors with N3 and M0."
  },
  {
    "prompt": "What defines Stage IVA lung cancer in TNM terms?",
    "completion": "Stage IVA includes any tumor size (Any T) and any nodal status (Any N) with M1a or M1b metastasis."
  },
  {
    "prompt": "What is the TNM classification for Stage IVB lung cancer?",
    "completion": "Stage IVB includes any tumor size (Any T) and any nodal involvement (Any N) with M1c metastasis."
  },


  {
    "prompt": "Can SCLC be staged using the TNM system?",
    "completion": "Yes, SCLC can be staged using the TNM system, but since SCLC is often systemic, a simpler staging classification has traditionally been used."
  },
  {
    "prompt": "What are the two main stages of SCLC according to the Veterans Affairs Lung Study Group (VALSG)?",
    "completion": "SCLC is classified into Limited Stage (LS-SCLC) and Extensive Stage (ES-SCLC) based on the VALSG classification."
  },
  {
    "prompt": "What defines Limited Stage Small Cell Lung Cancer (LS-SCLC)?",
    "completion": "LS-SCLC is confined to the ipsilateral hemithorax and local lymph nodes, including mediastinal, hilar, and supraclavicular nodes that can be encompassed within a single tolerable radiotherapy port. It corresponds approximately to TNM stages I through IIIB."
  },
  {
    "prompt": "What defines Extensive Stage Small Cell Lung Cancer (ES-SCLC)?",
    "completion": "ES-SCLC includes tumors that extend beyond the boundaries of limited disease, such as distant metastases, malignant pericardial or pleural effusions, contralateral supraclavicular lymph nodes, and contralateral hilar lymph node involvement."
  },
  {
    "prompt": "Is the TNM staging system widely accepted for SCLC?",
    "completion": "There is growing evidence that the TNM system may better define SCLC, but currently, there is no consensus on using it routinely for SCLC staging."
  },


  {
    "prompt": "What is the most significant factor affecting prognosis in patients with NSCLC?",
    "completion": "The TNM stage at presentation is the most significant factor impacting prognosis in patients with NSCLC."
  },
  {
    "prompt": "How does a higher TNM stage affect the prognosis of NSCLC?",
    "completion": "A higher TNM stage correlates with more advanced disease and poorer outcomes in NSCLC."
  },
  {
    "prompt": "What other clinical factors are indicative of poor prognosis in NSCLC?",
    "completion": "Poor performance status at diagnosis, anorexia, weight loss, and the presence of liver or skin metastases are indicative of poor prognosis in NSCLC."
  },
  {
    "prompt": "Do EGFR mutations affect prognosis in NSCLC patients?",
    "completion": "Yes, patients with activating EGFR mutations, especially in adenocarcinoma, have a better prognosis compared to those without these mutations."
  },
  {
    "prompt": "What is the key prognostic factor for Small Cell Lung Cancer (SCLC)?",
    "completion": "The extent of disease and stage at presentation are the most important prognostic factors for SCLC."
  },
  {
    "prompt": "What are the five-year survival rates for limited-stage versus extensive-stage SCLC?",
    "completion": "Patients with limited-stage SCLC have a five-year survival rate of 10 to 13%, whereas those with extensive-stage disease have a five-year survival rate of 1 to 2%."
  },
  {
    "prompt": "Are performance status and weight loss prognostic factors in SCLC?",
    "completion": "Yes, poor performance status and weight loss at the time of diagnosis are independent prognostic factors associated with decreased survival in SCLC."
  },


  {
    "prompt": "What are some common complications in patients undergoing treatment for lung cancer?",
    "completion": "Common complications include chemotherapy-induced nausea and vomiting, fatigue, anorexia, weight loss, anemia, neutropenia, nephrotoxicity, and neurotoxicities."
  },
  {
    "prompt": "Which chemotherapy-related complication is especially common with cisplatin-based therapies?",
    "completion": "Nephrotoxicity is especially common in patients receiving cisplatin-based therapies."
  },
  {
    "prompt": "What hematologic complications are common in lung cancer treatment?",
    "completion": "Anemia and neutropenia are common hematologic complications during lung cancer treatment."
  },
  {
    "prompt": "What are some systemic symptoms experienced by lung cancer patients during treatment?",
    "completion": "Fatigue, anorexia, and weight loss are common systemic symptoms in lung cancer patients undergoing treatment."
  },
  {
    "prompt": "What neurotoxicities may occur as complications in lung cancer treatment?",
    "completion": "Neurotoxicities can occur as side effects of lung cancer treatment, often related to certain chemotherapy agents."
  },


  {
    "prompt": "What is the single most important preventive measure for lung cancer?",
    "completion": "The single most important preventive measure is smoking cessation in all individuals."
  },
  {
    "prompt": "What screening method is recommended for primary prevention of lung cancer in high-risk individuals?",
    "completion": "Low-dose helical computed tomography (LDCT) is indicated for high-risk individuals for primary prevention."
  },
  {
    "prompt": "Which age group benefits more from lung cancer screening using LDCT?",
    "completion": "Smokers between the ages of 66 to 80 years benefit more from screening than those aged 55 to 64 years."
  },
  {
    "prompt": "Do patients without a history of smoking benefit from lung cancer screening?",
    "completion": "Patients without a history of smoking do not benefit from lung cancer screening."
  },
  {
    "prompt": "What factors besides smoking history are considered in lung cancer risk models for screening?",
    "completion": "Other factors include history of lung disease, family history of lung cancer, and asbestos exposure."
  },
  {
    "prompt": "What are the current USPSTF guidelines (2021) for lung cancer screening?",
    "completion": "The USPSTF recommends annual LDCT for patients aged 50 to 80 years with a ≥20 pack-year smoking history who currently smoke or quit within the past 15 years."
  },


  {
    "prompt": "What therapeutic options play a role in managing pain and symptoms in terminal lung cancer patients?",
    "completion": "Surgery, chemotherapy, and radiation all have roles in managing pain and other symptoms in terminal lung cancer patients."
  },
  {
    "prompt": "When is surgery considered beneficial for palliative care in lung cancer patients?",
    "completion": "Surgery is beneficial in patients with at least three months of expected survival and good performance status, especially with airway obstruction, hemoptysis, pleural or pericardial effusion, or brain or bone metastases."
  },
  {
    "prompt": "What percentage of lung cancer patients experience central airway occlusion, and how is it managed?",
    "completion": "Almost 30% of lung cancer patients experience central airway occlusion, managed with bronchoscopic laser destruction followed by stent placement for immediate relief."
  },
  {
    "prompt": "How does chemotherapy help in palliative care for lung cancer?",
    "completion": "Chemotherapy helps alleviate symptoms of pain and cough and may prolong survival."
  },
  {
    "prompt": "What is the role of radiation therapy in palliative lung cancer care?",
    "completion": "Palliative radiation provides symptomatic relief in 41% to 95% of lung cancer patients and plays a crucial role in alleviating pain due to brain and bone metastases."
  },
  {
    "prompt": "What endoscopic treatment is used to control symptoms due to airway narrowing in lung cancer?",
    "completion": "Endoscopic treatments such as brachytherapy help control symptoms due to airway narrowing."
  },


  {
    "prompt": "Why do outcomes for lung cancer remain poor despite advances in treatment?",
    "completion": "Most patients are diagnosed with advanced-stage disease, which significantly worsens outcomes."
  },
  {
    "prompt": "What role do primary care providers and nurse practitioners play in lung cancer diagnosis?",
    "completion": "They need to have a high suspicion of lung cancer in smokers and patients with occupational exposures and order appropriate imaging tests when indicated."
  },
  {
    "prompt": "Who is responsible for making the definitive diagnosis and management plan for lung cancer?",
    "completion": "The thoracic surgeon, in collaboration with the radiologist and pathologist, makes the definitive diagnosis and management plan."
  },
  {
    "prompt": "What are the nursing responsibilities after lung cancer surgery?",
    "completion": "Nurses monitor patients for oxygenation, ventilation, and pain, and remain vigilant for other comorbidities such as heart disease and peripheral vascular disease, communicating any abnormalities to the surgeon."
  },
  {
    "prompt": "What role does the oncology nurse play in lung cancer treatment?",
    "completion": "The oncology nurse educates patients about chemotherapy and radiation procedures and protocols during prolonged rehabilitation."
  },
  {
    "prompt": "How does the oncology pharmacist contribute to lung cancer patient care?",
    "completion": "Specialized oncology pharmacists educate patients about chemotherapeutic drugs, their benefits, and adverse effects, and consult with oncologists to tailor chemotherapy regimens based on patient response."
  },
  {
    "prompt": "What population is currently recommended for lung cancer screening according to guidelines?",
    "completion": "Men and women aged 55 years or older who have smoked 30 pack-years or more or quit smoking less than 15 years ago are recommended for lung cancer screening."
  },
  {
    "prompt": "What screening method is used for lung cancer detection?",
    "completion": "Low-dose helical CT scan of the chest, which takes less than 25 seconds, is used for lung cancer screening."
  },
  {
    "prompt": "What is a major drawback of lung cancer screening with low-dose CT?",
    "completion": "It can detect benign lesions, leading to unnecessary biopsies, surgeries, or prolonged radiological follow-up."
  },
  {
    "prompt": "How can clinical outcomes in lung cancer be improved according to the passage?",
    "completion": "Through close communication and collaboration within an interprofessional team that includes primary care providers, surgeons, radiologists, pathologists, nurses, and pharmacists."
  }
]


  




